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ABSTRACT
Large-scale projects such as the The Cancer Genome Atlas (TCGA) have generated exten-
sive exome libraries across several disease types and populations. Detection of somatic changes
in HLA genes by whole-exome sequencing (WES) has been complicated by the highly poly-
morphic nature of these loci. We developed a method POLYSOLVER (POLYmorphic loci
reSOLVER) for accurate inference of class I HLA-A, -B and -C alleles from WES data, and
achieved 97% accuracy at protein level resolution when this was applied to 133 HapMap sam-
ples of known HLA type. By applying POLYSOLVER in conjunction with somatic change
detection tools to 2688 tumor/normal pairs TCGA that were previously analyzed by conven-
tional approaches, we re-discovered 37 of 56 (66%) HLA mutations, while further identifying 23
new events. An analysis of WES data from a larger set of 3768 tumor/normal pairs by POLY-
SOLVER revealed 131 class I mutations with an enrichment for potentially loss-of-function
events. 3% of samples had at least one HLA event with 95 of 131 mutations in the T cell inter-
acting and peptide binding domains. Recurrent hotspot sites of missense, nonsense and splice
site mutations were discovered that suggest positive selection, and support immune evasion as
an important pathway in cancer.
Exome sequencing has also revealed a large number of shared and personal somatic mu-
tations across human cancers. In principle, any genetic alteration affecting a protein-coding
region has the potential to generate mutated peptides that are presented by surface HLA class I
proteins that might be recognized by cytotoxic T cells. Utilizing POLYSOLVER in conjunction
with knowledge of mutations in other genetic loci inferred from exome data, we developed a
pipeline for the prediction and validation of such neoantigens derived from individual tumors
and presented by patient-specific alleles of the HLA proteins. We applied our computational
pipeline to 91 chronic lymphocytic leukemias (CLL) that had undergone whole-exome sequenc-
ing. We predicted∼22 mutated HLA-binding peptides per leukemia (derived from∼16 missense
xvii
mutations), and experimentally confirmed HLA binding for ∼55% of such peptides. Finally,
we computationally predicted HLA-binding peptides with missense or frameshift mutations for
several cancer types and predicted dozens to thousands of neoantigens per individual tumor,
suggesting that neoantigens are frequent in most tumors. The neoantigen prediction pipeline
can also elucidate the neoantigens unique to a particular cancer patient and help in the design
of personalized immune vaccines.
MicroRNAs (miRs) are a class of non-coding small RNAs that regulate gene expression
by promoting mRNA degradation or by inhibiting mRNA translation. Context Likelihood of
Relatedness (CLR) is genetic network reconstruction method that considers the local network
context in assessing the significance of connections while also allowing for detection of non-
linear associations. Leveraging TCGA multidimensional data in glioblastoma, we inferred the
putative regulatory network between microRNA and mRNA using the CLR algorithm. Inter-
rogation of the network in context of defined molecular subtypes identified 8 microRNAs with
a strong discriminatory potential between proneural and mesenchymal subtypes. Integrative in
silico analyses, a functional genetic screen, and experimental validation identied miR-34a as a
tumor suppressor in proneural subtype glioblastoma. Mechanistically, in addition to its direct
regulation of platelet-derived growth factor receptor-alpha (PDGFRA), promoter enrichment
analysis of CLR−inferred mRNA nodes established miR-34a as a novel regulator of a SMAD4
transcriptional network. Clinically, miR-34a expression level is shown to be prognostic, where
miR-34a low-expressing glioblastomas exhibited better overall survival. This work illustrates
the potential of comprehensive multidimensional cancer genomic data combined with compu-
tational and experimental models to enable mechanistic exploration of relationships among
different genetic elements across the genome space in cancer.
1CHAPTER 1. GENERAL INTRODUCTION
Cancer is the second leading cause of death in the U.S. with 574,743 deaths recorded
in 2011 (http://www.cdc.gov/nchs/fastats/lcod.htm). Recent technological advances have en-
abled comprehensive characterization of genomic, expression, epigenetic and structural changes
accompanying this disease. This work addresses two exigent issues in current cancer research.
In the first part we explore the possibility of high fidelity typing of the highly polymorphic
HLA gene loci using whole exome data and expound on two applications: detection of so-
matic changes in HLA genes and identification of personal tumor-specific neoantigens. The
second part elucidates an integrative framework that utilizes mRNA and microRNA expres-
sion in conjunction with copy number and methylation data to infer the regulatory circuits of
microRNAs.
1.1 HLA typing and related applications
The Human Leukocyte Antigen (HLA) locus in the human genome comprises a set of highly
polymorphic genes that play an important role in the immune response. Exact determination
of HLA gene variants in an individual is known as HLA typing and has numerous applica-
tions including identification of compatible organ donors, understanding autoimmunity and
immune biology, and design of personalized cancer vaccines. HLA typing is typically a focused
effort informed by directed experimental protocols. Whole exome sequencing (WES, capture
sequencing), on the other hand, is a widely used technique for high-throughput sequencing of
the coding regions of genes across the genome. Although the use of WES as a research and
clinical tool is expanding exponentially, the non-specificity and relatively low-fidelity of WES
compared to directed experimental protocols makes it challenging to use this strategy for HLA
2typing. This work describes a computational method that enables high precision HLA typing
using WES data.
1.1.1 HLA genes and their function
The HLA genes are important effectors of the immune response in humans and are found in
all nucleated cells of the body. They bind aberrant endogenously processed peptides and present
them for recognition by the T-cells thereby inducing an immune response. The adaptive immune
response in humans depends upon the recognition of antigens presented either externally to
the system or those that correspond to endogenous foreign peptides. The latter can arise
when invading pathogens like viruses have successfully penetrated host cells through direct
infection or internalization by phagocytosis and their proteins are present internally in the host
cells. Host proteins that have acquired somatic changes through errors in DNA replication
or in the evolution of diseases such as cancer may also give rise to intracellular antigens. All
such aberrant proteins are processed by the cellular machinery into fragments that are 8-10
amino acids long and subsequently presented on the cell surface bound to specialized proteins
collectively referred to as the ’major histocompatibility complex’ (MHC). The destruction of
such cells is critically mediated by T cells that can recognize and respond to the MHC:peptide
complexes . There are two classes of MHC genes - I and II - that bind peptides corresponding
to proteins found in the cystosol and intracellular membrane-bound vesicles respectively. The
class I and II MHC genes also elicit responses from different T cell components. MHC genes are
also called human leukocyte antigen (HLA) genes in humans and the most well characterized
MHC class I genes are HLA-A, HLA-B and HLA-C. HLA genes are located on chromosome 6 of
the genome and have been implicated in several important roles such as graft-vs-host disease in
transplants and autoimmune disorders in addition to their pivotal role in cell-mediated immune
responses.
1.1.2 HLA diversity and nomenclature
HLA genes are inherited at birth and do not undergo widespread somatic changes in the life
of the organism. There is widespread heterogeneity at these loci across the population however
3and frequencies of HLA alleles vary by ethnicity. The IMGT database
(http://www.ebi.ac.uk/ipd/imgt/hla/) is a repository of all known HLA allele sequences and
has 2129 HLA-A, 2796 HLA-B and 1672 HLA-C recorded alleles (v3.10).
HLA allele nomenclature follows a convention where the name of the corresponding gene
is suffixed by successive sets of digits that correspond to decreasing functional relevance. The
first 2 sets of digits are the most important; the 1st set corresponds to the serological activity
of the allele and the second set to the protein sequence. For example, consider allele HLA-
A*02:01:01:01. All alleles that have the prefix HLA-A*02 (ex. HLA-A*02:01:01:01, HLA-
A*02:03:01) will elicit similar immune responses. All alleles with the same first 2 sets of
digits (ex. HLA-A*02:01:01:01, HLA-A*02:01:02) will also give rise to the exact same peptide
sequence, i.e they differ from each other only by synonymous changes.
1.1.3 Whole exome sequencing
Whole exome sequencing (WES, also referred to as capture sequencing), is a ubiquitous
technique that is used routinely in cancer analysis for characterization of somatic changes.
The technique is designed to sequence most of the exons, which constitute the protein-coding
regions in the genome, across the known set of genes. We have used Agilent’s SureSelect Target
Enrichment Workflow which comprises shearing genomic DNA followed by capture of exonic
regions with 120-mer biotinylated cRNA (complementary RNA) baits. The baits overlap in
sequence within an exon and comprise about 45 MB in total. The targeted exome region is 3˜3
MB in size. The capture step is followed by sequencing on Illumina machines generating 76
base pair long paired-end reads. The target coverage is 100x across the exome, with 80% of
the targets having > 20x coverage.
1.1.4 Motivation
Large-scale projects such as the TCGA (The Cancer Genome Atlas) have already generated
extensive exome libraries across several disease types and populations. Several issues with
capture sequencing including low coverage and difficulty of alignment in the HLA region have
prevented inference of HLA typing from capture data thus far. We describe here a high fidelity
4method to harness existing exome data for HLA typing focusing on HLA-A, HLA-B and HLA-
C genes. Knowledge of HLA alleles at a given locus would enable more sensitive mutation
detection in these genes. Combined with the knowledge of mutations in other genetic loci it
may further help elucidate potential immune escape mechanisms in cancer. Lastly, peptide
binding predictions may help elucidate the neoantigens unique to a particular cancer patient
and help in the design of personalized immune vaccines.
1.2 microRNAs and gene expression regulation
MicroRNAs(miRs) are a class of non-coding small RNAs produced by RNA polymerase II
as hairpins of longer precursor RNAs that are subsequently processed to approximately 22-
nucleotide-long fragments by RNase III enzymes, Drosha and Dicer. Mature miRs regulate
gene expression by promoting mRNA degradation or by inhibiting mRNA translation. The
connection between miRs and cancer was first implicated by their genomic alteration and
dysregulated expression in various human tumors. Multiple miRs have since been identified to
promote or suppress oncogenesis in various tumors, presumably by modulating gene expression
in the oncogenic and tumor suppressor networks.
1.2.1 Motivation
Several global analyses of miR:gene relationships have relied either on sequence-based inter-
action based methods or on general correlation coefficient methods. Correlation based methods
are restricted to detection of linear trends only. It would be revealing instead to utilize a more
general measure of association that is also sensitive to non-linear patterns. Moreover it would
be informative to study the significance of each miR:gene association in the context of the local
network defined by all possible edges involving the miR and gene molecules under consider-
ation. Such an approach would help to filter out those miRs and genes in the reconstructed
miR-mRNA network that have spurious similarities with large numbers of other gene/miR
species.
51.3 Dissertation organization
This dissertation comprises 3 main chapters, each corresponding to a journal article. Chap-
ter 2 describes a novel algorithm for HLA typing and detection of somatic changes in HLA
genes using whole exome data. Chapter 3 outlines a neoantigen discovery pipeline that implic-
itly uses the HLA typing algorithm developed in Chapter 2 and exemplifies the utility of this
pipeline in identifying neoantigens unique to individual patients as well as in estimating the
neoantigen load across different types of cancers. Chapter 4 describes a framework for inference
of regulatory connections of microRNAs based on integration of high-throughput expression,
copy number and methylation data with sequence based prediction databases.
1.4 Contribution
The chapters have been modified from the original journal articles to emphasize the aspects
that have been my original contributions. Chapter 2 is a computational paper in which I
have contributed to the conception and development of the POLYSOLVER algorithm and
the corresponding mutation detection framework, RNA-Seq validation, pan-cancer analysis of
mutations and assessment of functional impact of the discovered mutational spectrum. In
Chapter 3, I was responsible for development of the neoantigen discovery pipeline from exome
data, pan-cancer analysis and gene expression analysis. In Chapter 4, I have contributed to
the conception and development of the overall methodology, strategy for identification of most
discriminatory miRs between different subtypes of the disease, gene set enrichment, direct target
prediction, promoter analysis and development of the new miR:mRNA regulatory network
discovery approach that addresses the statistical issues discovered during application of the
Context Likelihood of Relatedness algorithm.
6CHAPTER 2. DETECTION OF SOMATIC CHANGES OF THE CLASS
I HLA LOCI USING EXOME SEQUENCING
Modified from a paper in preparation
Sachet A. Shukla, Mohini Rajasagi, Philip M. Dixon, Grace Tiao, Kristian Cibulskis, Adam
Kiezun, Carrie Sougnez, Catherine J. Wu?, Gad Getz?.
? denotes equal contribution
2.1 Introduction
Recent large-scale whole-exome sequencing (WES) efforts have revealed the existence and
relative high frequency of somatic changes in HLA class I genes in head and neck cancer, lung
cancer, and diffuse large B cell lymphoma (Stransky et al. (2011), TCGA (2012a), Lawrence
et al. (2014)). The HLA locus, located on chromosome 6, is among the most polymorphic
regions of the human genome, with thousands of documented alleles for each gene. Critical
mediators of the cytotoxic T cell response, these class I alleles serve to present intracellular
peptides on the cell surface by their encoded proteins in a form that can be recognized by
the T cell receptor. The findings of recurrent somatic mutations in HLA genes have strongly
suggested immune evasion as a positively selected pathway in the development and progression
of certain cancers.
Each individual expresses six major MHC class I alleles, with 3 alleles each inherited from
maternal and paternal genes. Conventionally, determination of HLA type is performed using
serology- and/or PCR-based methods that are labor-intensive and time-consuming. Although
7HLA typing information theoretically should be directly extractable from whole-exome sequenc-
ing (WES) data, a number of challenges to the precise and accurate detection of somatic HLA
mutations are evident. First, the highly polymorphic nature of this locus is expected to lead
to suboptimal alignment to canonical reference sequences which would generally be a misrep-
resentation of the true underlying individual haplotypes. Second, the HLA genes are GC-rich
and therefore apt to suffer from poor read retrieval due to lowered capture efficiency and po-
tential errors in sequencing, and subsequent difficulties in alignment. Overall, our hypothesis
was thus that conventional mutation detection methods underestimate somatic events within
this biologically important and complex locus.
To this end, we developed the algorithm POLYSOLVER (POLYmorphic loci reSOLVER),
which enables high precision HLA typing while using relatively low coverage WES data. This
was achieved through optimization of alignment followed by a novel model-based approach for
accurate inference of HLA class I alleles. By comparing cancer WES data from 3768 samples
against HLA typing inferred by POLYSOLVER from matched normal DNA, we improved the
sensitivity and precision for detecting somatic changes in HLA genes compared to conventional
mutation calling approaches. In principle, a similar approach may be applied to other highly
polymorphic regions of the genome, such as the class II loci, MIC genes and TAP genes. Our
approach is readily applicable to the growing body of WES datasets across human diseases
that rely on or are affected by antigen recognition.
2.2 Methods
2.2.1 Developing POLYSOLVER
As we expected with any region that is GC-rich, we confirmed that the HLA gene loci
within WES data from a well-characterized set of 8 Caucasian patients with chronic lympho-
cytic leukemia (CLL) (Wang et al. (2011)) demonstrated relatively poor capture efficiency and
less efficient sequencing and alignment. As shown in Suppl Figure 1, we observed that the
informative sites were preferentially enriched in regions of high GC content (p=5.7e-06) with
each of the three class I genes displaying a decreasing GC% trend in the direction of transcrip-
8tion (Figure 2.1). We also noted a marked inverse correlation of GC content with coverage in
each of HLA-A, B and C genes (corr=-0.51, p=4.6e-13) (median coverage at the HLA loci in
the 8 cases was 59 vs 89 median coverage in non-HLA sites). Naive alignment of the capture
reads to the canonical human genome in the HLA region was error-prone with only about 27%
of the reads aligning without mismatches or indels (Figure 2.2).
Figure 2.1 Relationship between GC%, informative site density and coverage in a typical HLA
gene
These observations motivated us to seek an alternate alignment strategy which would mit-
igate errors in alignment to hyperpolymorphic regions. We reasoned that optimal retrieval of
reads derived from HLA genes followed by accurate alignment to a library of all known HLA
alleles would serve as a solid foundation for subsequent computational inference. We therefore
developed a two-stage approach to infer HLA in which the first stage was to precisely perform
HLA alignments, while the second was to infer individual alleles by computing and ranking
posterior probability-derived scores (Figure 2.3).
2.2.2 Alignment
For the first stage, we sought to achieve high precision in HLA alignment by generating a
full-length genomic reference library of all known HLA alleles (6597 unique entries based on
the IMGT database (Robinson et al. (2013)). Sequence data and its alignments to a reference
9Figure 2.2 Example alignment of reads to the HLA gene sequences in the reference assembly
genome are usually stored as a BAM file, which is a binary version of the corresponding SAM
file (Sequence Alignment/Map format (Li et al. (2009))). To ensure maximal retrieval of true
HLA reads while restricting inclusion of reads that might result in spurious alignments to the
HLA loci, we performed a pre-selection step in which all reads mapping within 1 Kb of the HLA
genes were extracted from the processed BAM files. We moreover selected all reads perfectly
matching at least one bait in either orientation of a secondary library of unique 38-mer baits
generated from the HLA sequence library. Only the best-scoring alignments for each read were
preserved and used in the subsequent inference steps.
2.2.2.1 Polymorphic allele library creation
We constructed a reference library of known HLA alleles (6597 unique entries) based on the
IMGT database (v3.10; http://www.ebi.ac.uk/ipd/imgt
/hla/). Missing exons for incompletely sequenced allele cDNAs were deduced by multiple
sequence alignment of the missing allele with all available cDNA sequences. Missing introns
were inferred by alignment of the cDNA sequence with the nearest full-length genomic sequence.
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Figure 2.3 Schematic of the POLYSOLVER algorithm.
The final library comprised full-length genomic sequences of 2129 HLA-A, 2796 HLA-B and
1672 HLA-C alleles.
2.2.2.2 HLA read extraction and alignment from WES data
To maximally retrieve true HLA reads, we first extracted all reads mapping within 1 Kb
of the HLA genes from the processed BAM files. We then performed a further extraction by
using a secondary 38-mer HLA sequence library and ’fished’ for any reads perfectly matching
at least one tag in either orientation. We then realigned the pooled reads to the genomic
reference allele library using Novocrafts Novoalign software (http://www.novocraft.com). All
best-scoring allele matches for each read pair were preserved and used for subsequent allele
inference. Reads selected by this process are subjected to following post-processing filters prior
to inference of alleles: (i). reads with insertions or deletions are discarded (ii). both mates
must match the allele in question.
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2.2.2.3 Choice of tag library length
The choice of 38 mers for creation of HLA tag library was based on maximizing the specificity
of the library for HLA genes while maintaining 100% sensitivity in the context of downstream
read filtering. To assess the specificity of tag libraries of different lengths derived from the HLA
genes, we created a sequence set of 21,000 non-polymorphic genes and recorded the fraction
non-polymorphic genes that matched at least one tag from the library. Specificity was defined as
1 minus this fraction (Figure 2.4). To account for the possibility of sequencing errors or genuine
somatic mutations, we decided to preserve reads that had no more than one misalignment or
indel reference to the allele reference. For 100% sensitivity, this implies that the tag library
length be no more than half the length of the sequencing reads. If a misalignment happens at or
close to the edges of a read, there would still be multiple tags of length=(read length/2) in the
middle of the read which would guarantee its retrieval. In the extreme case, if a misalignment
happens in the middle base (if the read length is odd) or in one of the middle two bases (if the
read length is even), there would still be one tag of length=(read length/2) which would ensure
it’s retrieval. Since we had 76 base pair reads, we decided to use the 38 mer tag library, which
yielded a 23.3% specificity. The low specificity value is not an issue since non-specific reads are
discarded in the post-alignment filtering prior to the posterior probability computations.
2.2.3 First stage allele inference
We devised a posterior probability derived score, which was a measure of how likely it was
to see the observed set of HLA reads assuming a true underlying HLA allele. The two alleles
for each HLA gene were inferred in two different stages. Posterior probability derived scores
were calculated for each reference allele in the first stage. The likelihoods of all aligned read
pairs to a given allele were computed based on their respective alignments, quality scores and
insert size probabilities based on the empirical insert size distribution of all read pairs in the
sequencing run. Population-based allele probabilities were used as priors in the model. The
alleles that maximized the posterior probability derived scores were identified as one of the two
alleles at each locus in the sample.
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Figure 2.4 Specificity of tag libraries of different lengths
2.2.4 Posterior probability calculations
The posterior probability calculations for alleles corresponding to each HLA gene are per-
formed separately. We calculate a posterior probability derived score for each allele as described
below:
Let
M ≡# alleles corresponding to the HLA gene
N ≡# reads aligning to at least one allele
Nm ≡# reads aligning to allele am
NT ≡# reads in the sequencing run
fm ≡ population based prior probability of allele m. These frequencies were derived from
HLA typing studies conducted in various ethnic groups. For each ethnic group, the population
based frequency for an allele was estimated as the weighted average of the document frequencies
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in HLA typing studies for that ethnic group, where the weights were the number of individual
in each study.
rk1 ≡ first segment of read pair rk. Each sequenced read pair comprises two segments (also
called mates) that correspond to two ends of the same DNA fragment.
rk2 ≡ second segment of read pair rk
dk ≡ insert length of read pair rk
lk1 ≡ length of first segment of read pair rk
lk2 ≡ length of second segment of read pair rk
qi ≡ quality of sequenced base i. The quality of each base is determined by the instrument
at the time of sequencing and are finally stored in the BAM file.




We can use the quality scores of the alignment to build a model for the error generating
process. Let us say that a given read rk does in fact derive from an allele am and their
sequence relationship allowing for miscalls in the sequencing process is accurately captured in
the alignment. Let YAi, YCi, YGi and YT i denote random variables corresponding to observing
bases A, C, G and T respectively at position i in read rk in its alignment to allele am. Then
YAi, YCi, YGi, YT i ∼Multinomial(n = 1;αAi, αCi, αGi, αT i) (2.2)
where
αBi = 1− ei if reference base at position i in am is B
= ei3 otherwise
Let D denote a random variable for the observed insert length of a paired read in the
sequencing run based on alignment to the complete genome. For a given read pair rk, the
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empirical insert size distribution can be used to calculate the probability of observing the
insert length dk as
P (D = dk) =
∑NT
l=1 I(dl = dk)
NT
(2.3)
Assuming positional independence of quality scores, and independence of generated reads







αj · P (D = dk) (2.4)
The posterior probability of allele am is
P (am|r1, r2, . . . , rN ) =
∏N











We define a posterior probability derived score for allele am based on the log transformation














logP (D = dk) + log(fm) (2.7)
Read pairs that do not align to an allele are assumed to have zero probability of deriving
from that allele. The actual HLA alleles corresponding to the individual should have relatively
higher numbers of good alignments but direct score maximization would instead be biased
in favor of alleles with fewer mapped reads. This is accounted for by shifting the frame of
reference to sk, where sk is the theoretical least score achievable for read pair r
′
k with perfect
base qualities and segment lengths equal to those of rk. As we only preserve the best-scoring
alignments for each read pair, the contribution of a given read pair would be equal for all
matched alleles, and the read pair’s score contributions would maintain allele equality upon
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shift of reference. Since 93 is the maximum achievable base quality under Illumina 1.8+ format,
sk is computed as
sk = (lk1 + lk2) · log 10
−9.3
3
≈ −23 · (lk1 + lk2) (2.8)














logP (D = dk) + log(fm)−Nsk (2.9)
2.2.5 Second stage allele inference
Regarding the inference of the second class I HLA allele, a significant complicating factor
stems from the fact that any HLA gene in a given individual may be either a homozygous or
heterozygous allele. Since alleles corresponding to the same allele group or protein sequence
tend to have highly similar DNA sequences, we observed that selecting the top two alleles
when the posterior probabilities were simply sorted in order was incorrectly biased in favor
of declaring homozygous winners. On the other hand, a complete depletion of reads mapping
to the winning allele at the time of inference of the first allele followed by a recalculation
of the posterior probabilities yielded only heterozygous calls. To balance between these two
extremes such that we could reliably distinguish between homozygous and heterozygous second
alleles, we developed a heuristic for inference of the second allele that accounted for its sequence
similarity with the first inferred allele. This was accomplished by recalculating scores for the
second allele by first identifying reads that were also aligned to the first allele followed by
halving their alignment-based score contribution, while leaving the contribution of reads that
were exclusively aligned to the second allele intact. As in the first stage, the alleles with
maximal posterior probability derived scores for each gene were identified as the second alleles.
2.2.6 Detection of somatic mutations in HLA genes using POLYSOLVER
A common strategy for reliably identifying somatic mutations from WES data is to compare
matched tumor and germline (normal, unaffected tissue) capture sequencing data from the same
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individual while correcting for private SNPs within that same genome (Cibulskis et al. (2013)).
We considered the possibility that certain true somatic HLA mutations may be missed because
of lack of proper alignment in this region, which might be overcome by applying POLYSOLVER.
As represented schematically in Figure 2.5, we tested this idea by first applying POLYSOLVER
to germline WES data to infer the HLA type of the individual. This germline HLA sequence
then served as a synthetic reference against which pre-selected HLA reads from matched tumor
were compared, and mutations called by Mutect. We used Strelka (Saunders et al. (2012)) for
detection of insertions and deletions.
Figure 2.5 Framework for detection of somatic changes in HLA genes using POLYSOLVER.
Mutation detection algorithms Mutect and Strelka were incorporated for calling
point mutations and indels, following MHC-I typing of the germline by POLY-
SOLVER.
We first inferred the HLA type of the individual using the germline data. Reads that likely
derived from the HLA genes were pre-selected as described before from both tumor and germline
experiments. These two sets of reads were aligned separately to the HLA allele library. This
effectively simulated a mini paired tumor/normal HLA capture experiment for the individual
with the HLA allele library serving as a synthetic reference ’HLA genome’ and each allele
functioning as a ’chromosome’. The approach remains unaffected by the extremely high degree
of homology across the alleles since all the best alignments for each read are reported. Since a
significant portion of the reads mapped to multiple alleles, it was necessary to modify the tumor
and germline HLA genome-aligned BAM files such that the NotPrimaryAlignment bit flag was
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turned off and the mapping quality was changed to a non-zero value for all reads. These steps
were required to accurately run mutation detection tools such as Mutect which would otherwise
identify all alignments except one as secondary alignments, and therefore ignore them. Noisy
alignments where both mates did not align to the same reference allele as well as those where
at least one mate had more than one mutation, insertion or deletion event compared to the
reference allele were discarded prior to mutation calling. The MuTect algorithm (Cibulskis
et al. (2013)) was then applied to these BAMs to identify mutations and only those that
were reported in the inferred alleles for the individual were preserved. The Strelka software
(Saunders et al, 2012) was used for detection of somatic insertions and deletions in HLA genes.
The detected somatic changes were screened against a panel of normal variants created based
on 133 normal HapMap samples to reduce the rate of false positives. The remaining somatic
events were annotated for the gene compartment (intron, exon, splice site) and protein change.
2.2.7 Power calculation for RNA-Seq validation
We sought orthogonal validation of detected mutations that were identified exclusively by
POLYSOLVER, TCGA or commonly by both methods by probing available RNA-Seq data for
the corresponding samples from the CGHub resource. A mutation was considered validated
in RNA-Seq if there were at least 2 reads supporting the mutation. To determine the power,
we first calculated the allelic fraction of the mutation based on the exome data (p). Then,
given the total number of reads aligning at the position in the RNA-Seq data (N), power was
calculated as the probability that we would detect at least 2 reads bearing the alternate allele














WES from cases of chronic lymphocytic leukemia (CLL) patients has been previously re-
ported (Wang et al. (2011)). We used a subset of 8 CLL WES cases within this cohort for which
conventional PCR-based HLA typing information was also available to develop and train this
algorithm. By using the final developed method, we correctly identified 6 of 6 alleles in 7 cases
and 5 of 6 alleles in 1 case. In total, 47 of 48 (97.9%) alleles were identified correctly at the
protein level (Table 2.1). The misidentified allele had a population frequency of less than 0.05%
and was therefore missed by the algorithm. The data set had one homozygous case that was
correctly called.
Table 2.1 Test set: 8 CLL samples
HLA type # correct
CLL-100 HLA-A01:01 HLA-A03:02 HLA-B08:01 HLA-B44:03 HLA-C05:01 HLA-C07:02 6
CLL-024 HLA-A03:01 HLA-A01:02 HLA-B14:02 HLA-B38:01 HLA-C08:02 HLA-C12:03 5
HLA-A31:01
CLL-050 HLA-A02:01 HLA-A11:01 HLA-B44:02 HLA-B51:01 HLA-C05:01 HLA-C15:02 6
JP HLA-A11:01 HLA-A24:02 HLA-B51:01 HLA-B15:01 HLA-C03:03 HLA-C15:02 6
CLL-023 HLA-A02:01 HLA-A03:01 HLA-B35:01 HLA-B57:01 HLA-C04:01 HLA-C06:02 6
CLL-014 HLA-A02:01 HLA-A32:01 HLA-B44:02 HLA-B15:01 HLA-C05:01 HLA-C07:04 6
CLL-095 HLA-A02:01 HLA-A02:01 HLA-B38:01 HLA-B51:01 HLA-C05:01 HLA-C12:03 6
CLL 084 HLA-A01:01 HLA-A02:01 HLA-B08:01 HLA-B44:02 HLA-C07:01 HLA-C05:01 6
Protein level accuracy 47 (97.9%)
Allele group accuracy 47 (97.9%)
2.3.2 Validation of POLYSOLVER
We applied POLYSOLVER to WES data from a set of 133 HapMap samples comprising 15
Caucasians, 42 Blacks, 41 Chinese and 35 Japanese individuals with known HLA types (Erlich
et al. (2012); http://www.1000genomes.org)). As shown in Figure 2.6, 774 of 798 (97%) alleles
were identified correctly at the protein level resolution while allele groups were correctly typed in
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787 of 798 (98.7%) instances. There were no significant differences in performance by ethnicity
(94.4% - 98.8%), HLA gene (95.9% - 98.1%) or allele inference stage (96.7% - 97.2%). There
were 42 homozygous alleles in this set, all of which were correctly identified.
Figure 2.6 Application of POLYSOLVER of 133 HapMap samples.
2.3.3 Comparison to ATHLATES
POLYSOLVER was compared to ATHLATES (accurate typing of human leukocyte antigen
through exome sequencing) (Liu et al. (2013)), a program which infers HLA type from exome
data using an assembly-based approach. As stated in the original description of this algorithm,
ATHLATES requires higher coverage data than POLYSOLVER, with a minimum requirement
of 175 million pair-end reads and >= 10x coverage of at least 96% of the exons. By contrast, the
bulk of TCGA data has been reported to be much lower, with a median (range) of reads/sample
. Likewise, the median number reads of our validation set of 133 HapMap samples was 55 million
reads (range 37 - 149 million). Indeed, ATHLATES failed to call 75% (597/798) of the alleles in
the HapMap samples because of this relatively low coverage although its performance improved
with increasing library size. Of the ones that were called, it achieved a 68% (136/201) accuracy
at the 4-digit level. In contrast, POLYSOLVER consistently had >96% accuracy (96.5% -
100%) across the range of reads (Figure 2.7).
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Figure 2.7 Comparison of POLYSOLVER and ATHLATES. POLYSOLVER has good accu-
racy even for low coverage samples. Both algorithms were applied to the 133
HapMap set and the results compared by library size.
2.3.4 Comparison with HLA mutations identified using standard methods
The Cancer Genome Consortium (TCGA) has undertaken the comprehensive characteriza-
tion of several different cancer types across multiple data modalities. In order to test the validity
of this approach, we assembled a data set of 2688 cases of matched tumor and germline DNA
that had previously been analyzed using standard methods. 2437 of these samples were curated
from the TCGA and represented 10 diverse solid tumors (TCGA (2012a), Ding et al. (2008),
Stransky et al. (2011), TCGA (2012b), TCGA (2008), TCGA (2011), TCGA (2012c)), while
251 cases were separately collected from previously reported datasets of CLL cases (Wang et al.
(2011)) and melanoma (Hodis et al. (2012)). Mutation lists for lung squamous, lung adenocar-
cinoma, bladder, uterine, head and neck, colon and rectum, glioblastoma, ovarian and breast
were taken from the TCGA project (available through the Sage Bionetworks’ Synapse resource
(http://www.synapse.org/#!SYNAPSE:syn1729383). The list of mutations for melanoma and
chronic lymphocytic leukemia were obtained from the corresponding project resources respec-
tively (Wang et al, 2011; Hodis et al, 2012). There were 56 HLA gene (HLA-A, B and C)
21
mutations that were identified in these 2688 samples by standard approaches. These samples
were then analyzed by first typing with POLYSOLVER and then using Mutect and Strelka as
described previously. This approach could identify only 37/56 mutations that were identified by
standard methods, and detected 23 additional mutations (Figure 2.8, Figure 2.9). Visualization
by IGV suggested that most of the mutations that were identified exclusively in SYNAPSE
may be false positives. On the other hand, mutations that were identified exclusively by the
POLYSOLVER+mutation detection approach seem to have good sequence based support.
Figure 2.8 Comparison of somatic mutations identified by TCGA across cancers using stan-
dard approaches to those identified by the POLYSOLVER framework (n=2688).
We reasoned that presence of detected mutations in individual-matched transcriptomic data
(RNA-Seq) would provide independent confirmation of these events. We focused exclusively on
mutations that had RNA-Seq data available and also were adequately powered for mutation
detection (Figure 2.10). Most of the current RNA-Seq alignment methods including MapSplice
have poor recall for detecting insertions and deletions (Engstrom et al, 2013).
All of the 11 missense mutations that were identified by POLYSOLVER and standard
approaches were validated at the RNA-Seq level. The allelic fraction of the mutations in the
expression data varied from 8% to as high as 98%. In case of 7 missense mutations that were
unique to POLYSOLVER, the validation rate was 71% (5/7) with allele fraction in the 6-38%
range. None of the 5 mutations that were uniquely identified by TCGA were validated at the
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Figure 2.9 Comparison of HLA mutations identified by standard methods and POLYSOLVER
by tumor type (SKCM = Melanoma, LUSC = Lung squamous cell carcinoma,
LUAD = Lung adenocarcinoma, BLCA = Bladder, HNSC = Head and neck,
COAD = Colon adenocarcinoma, READ = Rectum adenocarcinoma, UCEC =
Uterine, GBM = Glioblastoma multiforme, OV Ovarian, BRCA = Breast, CLL =
Chronic lymphocytic leukemia).
expression level. The rate of RNA-Seq detection of nonsense and non-stop mutations was 75%
(9/12 and 3/4) for events that were identified by both methods and those that were detected
by exclusively by POLYSOLVER, while neither of the two events identified by TCGA alone
had any mutation-bearing reads in RNA-Seq data. A similar pattern was observed for splice
site mutations with similar validation rates for events in the common and POLYSOLVER
exclusive categories (2/3 and 3/4 respectively), whereas the only such event that was unique
to the TCGA resource could not be confirmed. These results suggest that our framework is
both more sensitive and specific in detection mutations in these highly polymorphic loci than
conventional methods.
2.3.5 Mutational spectrum of HLA class I genes and their functional effects
We then applied the POLYSOLVER driven mutation detection framework to an extended
set of 3768 samples by including an additional 1080 TCGA samples to our original collection of
2688 tumor/normal pairs. In total, 131 somatic HLA mutations were detected in 114 of 3768
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Figure 2.10 Validation of mutations at the transcriptomic level. Mutations identified by
POLYSOLVER using DNA sequencing were validated at the transcriptome level
using RNA sequencing of the same samples.
(3%) of individuals. Events in HLA-A and HLA-B comprised 43.5% and 39.7% of the total
number of mutations respectively, whereas HLA-C only had 16.8% of the events (Figure 2.11).
The identified mutations were not restricted a gene loci, mutation class or spectrum (Figure
2.11, Figure 2.12). The highest frequency of mutations occurred in exon 4 (35.1%) that encodes
the alpha-3 domain of the HLA protein that binds to the CD8 co-receptor of T cells. Abrogation
of this function could lead to a loss of T cell recognition and thereby lead to a loss of immune
response. A mutation in alpha 3 domain in residues 223–229 can prevent low avidity T cells
from binding to MHC/peptide complex (Pittel et al, 2003). About 13% of exon 4 mutation
(6/46) were found in this region in our data set were found in this region.
About 37.4% of mutations were found in exons 2 and 3 that code for the alpha1 (13%)
and alpha2 (24.4%) peptide binding domains. These domains bind the peptide that is usually
9 amino acids long and the MHC:peptide complex is then transported to the cell surface
for recognition by cytotoxic T cells. Several residues on the HLA molecule are known to
interact with specific positions of the binding peptide (Brusic et al. (2002)). There are two
major anchor grooves in the HLA molecule that bind to positions 2 and 9 respectively of
the peptide and mutation in either one could lead to a profound effect on the biochemical
stability of the MHC:peptide complex. A secondary anchor groove that interacts primarily
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Figure 2.11 Distribution of HLA mutations across exons.
with the sixth amino acid of the peptide lies between the two primary anchor grooves. 25%
of mutations (12/49) in the peptide binding domains were in residues that come in contact
with the peptide and 9 of these were in positions that comprised one of the two primary anchor
grooves. Interestingly, most of these mutations (7/9) were in the second primary groove (Figure
2.13). In addition, 5 of the 12 HLA contact residue mutations can potentially interact with the
secondary anchor groove.
A significant number of mutations also occur in exon 1 (11.5%) which is translated to create
the leader sequence that helps in correct localization of the MHC molecule. An abundance of
truncating and frameshifting events were detected in this exon which could lead to a complete
deletion of the protein.
9.9% of mutations were in exon 5 which encodes for the transmembrane region. Mutations
in this domain might result in an inability of the MHC molecule to anchor itself on the cell
membrane or incorrect localization.
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Figure 2.12 Comparison of spectrum of mutations in non-HLA genes and HLA genes. The ra-
tio of number of mutations of a particular types to the number of silent mutations
is compared between the non-HLA and HLA genes for all mutation types.
The least number of mutations were recorded in the cytoplasmic tail encoded by exons 6
and 7 (4.6%) Surprisingly, 2 non-stop mutations were also recorded, which may cause decrease
of transcript levels by mRNA degradation due caused by a missing polyA tail.
We compared the ratio of the number of somatic changes to the number of silent mutations
in HLA and non-HLA genes (Figure 2.12). This ratio is around 2.5 for both categories, which
suggests that most missense mutations in HLA genes accrue as a result of systemic dysregulation
of DNA repair and other error correcting mechanisms that accompany malignancy and are
therefore non-causative passenger mutations. However this ratio is significantly enriched for
nonsense, splice site and frameshift indels in HLA genes compared to the non-HLA genes. While
nonsense mutations profoundly affect protein function due to truncation, frameshift indels can
also potentially have a significant effect the expression levels of the alleles by activating mRNA
degradation pathways. Splice site mutations may similarly affect mRNA or protein structure
as a result of aberrant splicing or intronic retention. These results suggest that HLA mutations
are significantly enriched for loss-of-function events.
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Figure 2.13 HLA mutations in contact residues. Contact residues in the HLA molecules are
in actual physical contact with the peptide.
2.3.6 Patterns of HLA mutations across tumor types
We observed a wide disparity in the frequency and nature of HLA mutations across the 12
tumor types in our data set (Figure 2.14). Colon, head and neck, melanoma and lung squa-
mous tumors had the highest frequency of HLA mutations (mutations/sample) while breast,
glioblastoma and ovarian had the lowest. Although melanoma had a high rate of HLA muta-
tions, there were in fact fewer observed mutations that expected based on the average mutation
rate in these samples derived from non-HLA genes. Colon cancer was the only tumor types
where there was clear evidence of mutations in more than one HLA allele in the same sample
which might indicate increased significance of HLA mutations in this disease. The contrast
between the HLA mutation spectrum betwen colon and rectal is also striking given how similar
they are otherwise. While there seem to be certain preferred mutational hotspots, somatic
changes, particularly loss-of-function events like nonsense and frameshifting events were found
in all functional domains.
We also observed several positions with recurrent events, which might be indicative of their
biological relevance as important driver events in the development or progression of the disease.
The ”hotspot” mutation positions comprised events across HLA genes, tumor and mutation
types, and we did not detect position-dependent tumor or gene specific effects with a few notable
exceptions. Residue 7, along with residue 209, was the most frequently mutated position with
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a preponderance of truncating mutations that were all exclusively in head and neck samples.
Residue 209 in present at the 5’ end of the TCR binding domain and is characterized by
insertions in primarily colon cancer patients. There were three recurrent splice site mutation
positions spanning the junctions between exons 1 and 2, 3 and 4 and 4 and 5. Also notably
bladder was the only tumor type with two recurrent non-stop mutations.
2.4 Discussion
The application of the described framework for detection of mutations in HLA-A, B and C
genes across thousands of characterized samples yielded many more mutations that were missed
by standard mutation detection techniques. A preliminary visualization suggests that disclosed
example method is both more sensitive and specific compared to existing techniques. The
improved performance can be attributed to (i) using the correct reference allele sequences, (ii)
preselection of reads corresponding to HLA genes, (iii) using a precise alignment algorithm, and
(iv) judicious post-filtering of the alignments prior to mutation calling. Since immune evasion
is an important mechanism for the development and progression of cancer, the acquisition of
somatic changes in HLA regions may be an important driver or abetting events in at least some
of the patients. This hypothesis is supported by the fact that recurrent HLA mutations, as
well as mutations in exons 2 and 3 responsible for coding the peptide binding domains that
are primarily responsible for presentation of the aberrant peptides to the immune system are
regularly found.
A framework for inference of constituent alleles and more sensitive and specific detection
of somatic changes in polymorphic loci such as HLA by first inferring the correct reference
sequences for these genes using relatively low coverage exome or other types of sequencing data
has been described in this work. The framework can harness multiple different somatic change
algorithms and leverage their individual strengths. This example methodology will assist in
gleaning knowledge from the vast repositories of sequence data that have been generated thus
far. Newer sequencing technologies are enabling increased coverage and longer read lengths,
which would help further in resolving polymorphic loci into their correct constituent alleles and
lead to increasingly better performance of the framework.
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Figure 2.14 Pan-cancer distribution of HLA mutations across functional domains/exons. Dis-
tribution of HLA mutations across functional domains and tumor types. Potential
loss-of-function events were found to be distributed across the length of the pro-
tein, denoted by the blue (out of frame indels) and red (nonsense mutations)
dots across the top. The histogram immediately below summarizes the num-
ber of events identified at each positions. The vertical panel on the left shows
the expected versus observed number of mutations for each disease type. The
central panel shows patterns of mutations detected in each tumor type. There
were several positions with recurrent events; the lowermost panel depicts recur-
rent positions with frequency >= 3. The disease and allele group of the detected
mutations are also indicated in this panel.
29
CHAPTER 3. SYSTEMATIC IDENTIFICATION OF PERSONAL
TUMOR-SPECIFIC NEOANTIGENS IN CHRONIC LYMPHOCYTIC
LEUKEMIA
Modified from a paper submitted to Blood 2014
Mohini Rajasagi, Sachet A. Shukla, Edward F. Fritsch, Derin B. Keskin, David DeLuca,
Ellese Carmona, Wandi Zhang, Carrie Sougnez, Kristian Cibulskis, John Sidney, Kristen
Stevenson, Jerome Ritz, Donna Neuberg, Vladimir Brusic, Stacey Gabriel, Eric S. Lander,
Gad Getz, Nir Hacohen, and Catherine J. Wu
3.1 Introduction
Recent progress in the development of potent vaccine adjuvants, clinically effective vaccine
delivery systems and agents that overcome tumor-induced immunosuppression has been strik-
ing, and strengthens the possibility that long-awaited effective therapeutic cancer vaccines are
feasible (Hodi et al. (2010), Topalian et al. (2012), Taneja (2012), Mellman et al. (2011)). How-
ever, the problem of antigen selection for cancer vaccines has remained an unsolved challenge.
A review of past cancer vaccine efforts has revealed a general lack of efficacy that may stem
from their focus on overexpressed or selectively expressed tumor-associated native antigens as
vaccine targets (Boon et al. (2006), Rosenberg et al. (2004)). Mounting an effective response
against these native immunogens requires overcoming the challenging hurdles of breaking cen-
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tral and peripheral tolerance, while risking the generation of autoimmunity (Mellman et al.
(2011)). The rare examples of successful cancer vaccines in humans have targeted foreign
pathogen-associated antigens (van der Burg and Melief (2011)), idiotype vaccines derived from
patient-specific rearranged immunoglobulins (Baskar et al. (2004)), or a vaccine based on a mu-
tated growth factor receptor (Nedergaard et al. (2012)). These contrasting studies point to the
importance of selecting immunogens that are distinct from self, where central and peripheral
tolerance are not an issue and the risk of autoimmunity is lower.
A primary hallmark of tumorigenesis is the accumulation of mutations in cancer cells.
These mutations are found both in genes that drive cancer, and those that do not (passen-
ger mutations) (Garraway and Lander (2013)). Regardless of driver status, these mutations
provide a potential opportunity to specifically target tumor cells through the creation of tu-
mor specific novel immunogenic peptides (neoantigens). These neoantigens are generated from
peptides encoded by gene alterations that are present in tumor but not normal tissue, and
therefore represent highly promising vaccine immunogens (Hacohen et al. (2013), Heemskerk
et al. (2013)). Seminal studies have suggested the immunotherapeutic potential of neoantigens
and have shown that: (a) mice and humans can mount T cell responses against mutated anti-
gens (Sensi and Anichini (2006), Parmiani et al. (2007)); (b) mice can be tumor-protected by
immunization with a single mutated peptide present in the tumor (Mandelboim et al. (1995));
and (c) memory cytotoxic T lymphocyte (CTL) responses to mutated antigens are generated in
patients who have unexpected long-term survival or have undergone effective immunotherapy
(Lennerz et al. (2005), Zhou et al. (2005)). However, neoantigens also are almost exclusively
personal, found uniquely in the tumor of each individual patient, and therefore have not been
used for immunotherapy due to technical difficulties in their identification and testing (Sensi
and Anichini (2006)).
Two recent technologies have now overcome this limitation. First, massively-parallel se-
quencing has now enabled not only the analysis of putative driver genes and pathways across
various cancers (Garraway and Lander (2013), Vogelstein et al. (2013)), but also the compre-
hensive identification of the tens to thousands of somatic protein-coding mutations which may
create epitopes that can be recognized immunologically in an individual- and tumor-specific
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fashion. Second, refinements in class I HLA prediction algorithms have enabled the reliable
prediction of peptide binding for a broad range of class I HLA alleles (Lin et al. (2008), Zhang
et al. (2011)).
Herein, we report that putative neoantigens identified though sequential application of mas-
sively parallel sequencing followed by HLA binding prediction are immunogenic in humans and
can target malignant cells in a tumor-specific fashion. Initially, we focused on chronic lympho-
cytic leukemia (CLL), a common adult B cell malignancy that remains largely incurable but
is potentially immune-responsive on the basis of reports of spontaneous regression and suscep-
tibility to the graft-versus-leukemia effect (Dores et al. (2007), Zenz et al. (2010), Del Giudice
et al. (2009)). Based on leukemia-specific gene mutations that we identified in patients with
CLL (Landau et al. (2013), Wang et al. (2011)), we predicted candidate leukemia neoanti-
gens and then monitored neoantigen-specific memory T cell responses in patients who had
undergone allo-HSCT (Burkhardt et al. (2013)). Our approach demonstrates the feasibility of
identifying immunogenic neoantigens and provides a basis for designing a truly personalized
immunotherapeutic vaccine in humans.
3.2 Methods
3.2.1 A pipeline for the systematic identification of tumor neoantigens
We leveraged recent advances in sequencing technologies and peptide epitope prediction to
generate a two-step pipeline to systematically discover candidate tumor-specific HLA-bound
neoantigens. As depicted in Figure 3.1, we began with DNA sequencing of tumors (by either
whole-exome (WES) or whole-genome sequencing (WGS)) in parallel with matched normal
DNA, followed by comprehensive identification of tumor specific non-synonymous somatic mu-
tations (Lawrence et al. (2013), Cibulskis et al. (2013)). Next, we used the well-validated
prediction algorithm, NetMHCpan, to predict candidate tumor specific mutated peptides with
the potential to bind personal class I HLA proteins and hence be presented to CD8+ T cells
(Zhang et al. (2011)). Finally, to identify a smaller number of epitopes for deeper investigation,
we selected a subset of candidate peptide antigens based on experimental validation of their
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binding to HLA and expression of cognate mRNAs in autologous leukemia cells.
Figure 3.1 Schematic representation of a strategy to systematically discover tumor neoanti-
gens. Tumor specific mutations in cancer samples are detected using whole-exome
(WES) or whole-genome sequencing (WGS) and identified through the application
of mutation calling algorithms (such as Mutect) (Cibulskis et al. (2013)). Next,
candidate neoepitopes can be predicted using well-validated algorithms (NetMHC-
pan) and their identification can be refined by experimental validation for pep-
tide-HLA binding and by confirmation of gene expression at the RNA level. These
candidate neoantigens can be subsequently tested for their ability to stimulate
tumor-specific T cell responses.
3.2.1.1 Whole exome capture sequencing data for CLL and other cancers
The list of somatic mutations detected in the 91 CLL patients used in this study has been
previously reported (Wang et al. (2011)). The list for melanoma was obtained from dbGaP
database (phs000452.v1.p1) and for the 11 other cancers, through TCGA (available through the
Sage Bionetworks’ Synapse resource
(https://www.synapse.org/#!Synapse:syn1729383)). We genotyped the HLA-A, HLA-B and
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HLA-C loci in 2488 samples across these 13 tumor types using POLYSOLVER, as described in
Chapter 2.
3.2.1.2 HLA typing from exome capture data
We developed the POLYSOLVER (POLYmorphic loci reSOLVER) algorithm that would
enable HLA typing of HLA -A, -B and C alleles of individuals using capture data (please see
Chapter 2 for details). We constructed a dedicated sequence library consisting of all known HLA
alleles (6597 unique entries), based on the IMGT database. From this resource, a secondary
library of 38-mers was generated, and putative reads emanating from the HLA locus were
extracted from total sequence reads based on perfect matches against it. The extracted reads
were then aligned to the IMGT-based HLA sequence library using the Novoalign software
(http://novocraft.com), and HLA alleles were inferred through a two-stage calculation. In the
first stage, population-based frequencies were used as priors for each allele and the posterior
probability derived scores were calculated based on quality and insert size distributions of
aligned reads. Alleles with the highest scores for each of HLA-A, B and C genes were identified
as the first set of alleles. A heuristic weighting strategy of the computed scores in conjunction
with the first set of winners were then used to identify the second set of alleles.
3.2.1.3 Pipeline for prediction of peptides derived from gene mutations with
binding to personal HLA alleles
MHC-binding affinity was predicted across all possible 9-mer and 10-mer peptides gener-
ated from each somatic mutation and the corresponding wildtype peptide using NetMHCpan
(Version 2.4). These tiled peptides were analyzed for their binding affinities (IC50 nM) to each
class I allele in the patients HLA profile. An IC50 value of less than 150 nM was considered
a predicted strong binder, an IC50 of 150–500 nM was considered a predicted intermediate to
weak binder, while an IC50 > 500 nM was considered a non-binder. Experimental confirma-
tion of predicted peptides binding to HLA molecules (IC50 < 500 nM) was performed using a
competitive MHC class I allele-binding assay and has been described in detail elsewhere (Cai
et al. (2012), Sidney et al. (2001)).
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3.2.2 Analysis of CLL gene expression
CTL responses against an epitope would only be useful if the gene encoding the epitope is
expressed in the target cells. Of the 31 patient samples sequenced and typed for HLA, 26 were
subjected to genome-wide expression profiling (Brown et al. (2012)). We reanalyzed previously
reported microarray data (NCI Gene Expression Omnibus accession GSE37168). Affymetrix
CEL files were processed using the affy package in R. The Robust Multichip Analysis (RMA)
algorithm models the observed intensities as a mixture of exponentially distributed signal and
normally distributed noise and was used for background correction. This was followed by
quantile normalization across arrays to facilitate comparison of gene expression under different
conditions. The individual probe-level was finally summarized using the median polish approach
to get robust probeset-level values (Bolstad et al. (2003), Irizarry et al. (2003)). Gene-level
values were obtained by selecting the probe with the maximal average expression for each gene.
Batch effects in the data were removed by using the Combat program (Johnson et al. (2007)).
3.3 Results
3.3.1 Frequency of missense and frameshift mutations in 91 CLL samples
We applied this pipeline to a large dataset of sequenced CLL samples (Wang et al. (2011)).
From 91 cases that were sequenced by either WES or WGS, a total of 1838 non-synonymous
mutations were discovered in protein-coding regions, corresponding to a mean somatic mutation
rate of 0.72 (0.36 s.d.) per megabase (range, 0.08 to 2.70), and a mean of 20 non-synonymous
mutations per patient (range, 2 to 76). We identified 3 general classes of mutations that would
be expected to generate amino acid changes and hence potentially be recognized immunolog-
ically as non-self. The most abundant class consisted of missense mutations that cause single
amino acid changes, representing 90% of somatic mutations per CLL. Of the 91 samples, 99%
harbored missense mutations and 69% had between 10-25 missense mutations (Figure 3.2A).
The other two classes of mutations, frameshifts and splice-site mutations (mutations at exon-
intron junctions) have the potential to generate longer stretches of novel amino acid sequences
entirely specific to the tumor (neo-open reading frames, or neoORFs), with a higher number
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of neoantigen peptides per alteration (compared to missense mutations). However, consistent
with data from other cancer types (Lawrence et al. (2013)), neoORF-generating mutations were
∼10 fold less abundant than missense mutations in CLL (Figure 3.2B-C). Given the prevalence
of missense mutations, we focused our initial studies on the analysis of neoantigens generated
from this class of mutations.
3.3.2 Somatic missense mutations were predicted to generate neopeptides that
bind personal HLA class I alleles
T cell recognition of peptide epitopes by the T cell receptor (TCR) requires the display of
peptides bound within the binding groove of HLA molecules on the surface of antigen-presenting
cells. Recent comparative studies across the >30 available class I prediction algorithms have
shown NetMHCpan to consistently perform with high sensitivity and specificity across HLA al-
leles (Zhang et al. (2011)). To assess the predictive capacity of NetMHCpan, we tested whether
the algorithm would correctly predict binding for 33 mutated epitopes that were already identi-
fied in the literature on the basis of their functional activity (i.e. ability to stimulate antitumor
cytolytic T cell responses) or were characterized as immunogenic minor histocompatibility anti-
gens (Table 3.2,3.3). Among all tiled 9-mer and 10-mer possibilities, NetMHCpan identified
all 33 functionally validated mutated epitopes as the best binding peptide among the possible
choices for the given mutation. We observed that the median predicted binding affinity (IC50)
to the reported HLA restricting elements for each of the 33 mutated epitopes was 32 nM (range,
3-11,192 nM). By setting the predicted IC50 cut-offs to 150 and 500 nM, we could capture 82
and 91% of the functionally validated peptides, respectively (Figure 3.2A) (Sette et al. (1994)).
On the basis of its high degree of sensitivity and specificity, we then applied NetMHCpan
prospectively to the 31 of 91 CLL cases for which HLA typing information was available (Wang
et al. (2011)). We considered peptides with IC50 < 150 nM as strong binders, IC50 150-500 nM
as intermediate to weak binders, and IC50 > 500 nM as non-binders, respectively (31). For 91
CLL cases, we found a median of 10 strong binding peptides (range, 2-40) and 12 intermediate
to weak binding peptides (range, 2-41) per case. Hence, in total, a median of 22 (range, 6-81)
peptides per case was predicted with IC50< 500 nM (Fig. 3.2B, table 3.3).
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Figure 3.2 Frequency of classes of point mutations that have the potential to generate neoanti-
gens in CLL. Analysis of WES and WGS data generated from 91 CLL cases reveals
that (A) missense mutations are the most frequent class of the somatic alter-
ations with the potential to generate neo-epitopes, while (B) frameshifts and (C)
splice-site mutations constitute rare events.
3.3.3 More than half of predicted HLA-binding neopeptides showed direct bind-
ing to HLA proteins in vitro
To experimentally validate the predicted IC50 nM scores, we performed a competitive MHC
I allele binding assay (Sidney et al. (2001)) and focused on class I-A and B alleles. To this end,
we synthesized 112 mutated 9- or 10-mer peptides, with predicted IC50 scores of less than 500
nM, identified from 4 CLL cases (Pt 1-4). The experimental results correlated with the binding
predictions. Experimental binding (defined as IC50 < 500 nM) was confirmed in 76.5% and
36% of peptides predicted with IC50 of < 150 nM or 150-500 nM, respectively (Figure 3.2C).
In total, ∼55% (61/112) of predicted peptides were experimentally validated as binders to
personal HLA alleles.
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3.3.4 80% of mRNAs encoding predicted neoantigens are expressed in CLL
We classified the expression level of 347 genes (that harbor mutations in CLL samples) as
low/absent (lowest quartile), medium (middle two quartiles) or high (highest quartile) expres-
sion. As shown in Figure 3.2D, 80% of the 347 mutated genes (or 79% of the 180 mutations
with predicted HLA-binding) were expressed at medium or high expression levels.
3.3.5 Large numbers of candidate neoantigens were predicted across diverse can-
cers
The overall somatic mutation rate of CLL is similar to other blood malignancies, but low in
comparison to solid malignancies (Lawrence et al. (2013)) (Figure 3.5A). To examine how tumor
type and mutation rate could impact the abundance and quality of candidate neoantigens,
we applied our pipeline to publicly available WES data from 13 malignancies including high
(melanoma (MEL), lung squamous (LUSC) and adeno (LUAD) carcinoma, head and neck
cancer (HNSC), bladder cancer, colon and rectum adenocarcinoma), medium (glioblastoma
(GBM), ovarian, clear cell renal carcinoma (clear cell RCC), breast cancer) and low (CLL,
acute myeloid leukemia (AML)) mutation rate cancers. To perform this analysis, we further
implemented a recently developed algorithm that enables inference of HLA typing from WES
data (see POLYSOLVER, Chapter 2).
The mutation rate in these solid malignancies was an order of magnitude higher than for
CLL and was associated with an increased median number of missense mutations. For example,
melanoma displayed a median of 300 (range, 34-4276) missense mutations per case, and while
RCC had 41 (range, 10-101), respectively. Frameshift and splice-site mutations in melanoma
and RCC were increased by only 2-3 fold in frequency as compared to CLL and summed neoORF
length per sample were increased only moderately (by 5-13 fold). Overall, the median number
of predicted neopeptides with IC50 < 500 nM generated from missense and frameshift events
per sample was proportional to the mutation rate; this was approximately 20- and 4-fold higher
for melanoma (488; range, 18-5811) and RCC (80; range, 6-407)), respectively, compared to
CLL (24; range 2-124). With a more stringent threshold of IC50 < 150 nM, the corresponding
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Table 3.1 Distribution of mutation classes, summed neoORF sizes and number of predicted
binding peptides across 13 cancers
numbers of predicted neopeptides per sample were 212, 35 and 10 for melanoma, RCC and
CLL, respectively (Figure 3.5, Table 3.1).
3.4 Discussion
Each individual tumor harbors a broad spectrum of shared and personal genetic alterations
that continue to evolve in response to the environment and often lead to resistance to therapy
(Garraway and Lander (2013)). Given the uniqueness and plasticity of tumors, an optimal
therapy may need to be customized based on the exact mutations present in each tumor and
may need to target multiple nodes to avoid resistance (Ene and Fine (2011), Longo (2012),
Greaves and Maley (2012), Nazarian et al. (2010)). The vast repertoire of human CTLs has
the potential to create such a therapy that targets multiple, personalized tumor antigens.
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This opportunity motivated us to develop a pipeline that systematically identifies CTL target
antigens harboring tumor-specific mutations. Leveraging massively parallel sequencing and
algorithms that effectively predict HLA-binding peptides, we predicted tumor neoantigens in a
variety of low and high mutation rate cancers, and experimentally identified long-lived CTLs
that target leukemia neoantigens in CLL patients. Our results, together with recent studies
in humans (Robbins et al. (2006)) and mice (Castle et al. (2012)), support the existence of
protective immunity targeting tumor neoantigens, and our pipeline provides a method for
selecting neoantigens for future personalized tumor vaccines.
We applied our pipeline to a unique group of CLL patients who developed clinically evident
durable remission associated with anti-tumor immune responses following allogeneic-HSCT.
These graft-versus-leukemia responses have typically been attributed to allo-reactive immune
responses targeting hematopoietic cells (Bleakley and Riddell (2004)). However, we now find
that the GvL response is also associated with CTLs that recognize personal leukemia neoanti-
gens. These results are consistent with prior studies by our group and others demonstrating
the existence of GvL-associated CTLs with specificity for tumor- rather than allo-antigens
(Burkhardt et al. (2013), Nishida et al. (2009), Zhang et al. (2010)). Further supporting the
importance of neoantigen-reactive CTLs in cancer surveillance, an elegant study of a long-term
melanoma survivor found that CTLs targeting neoantigens are significantly more abundant
and sustained than those against non-mutated overexpressed tumor antigens (Lennerz et al.
(2005)). In agreement with the melanoma study, we found that neoantigen-specific T cell re-
sponses in CLL patients were long-lived (on the order of several years) memory T cells (based
on their rapid stimulation kinetics in vitro) and associated with continuous disease remission
(Lu et al. (2013)). We thus hypothesize that neoantigen-reactive CTLs play an active role in
controlling leukemia in transplanted CLL patients.
More generally, we estimated the abundance of neoantigens across many tumors and found
∼1.5 HLA-binding peptides with IC50<500nM per point mutation and ∼4 binding peptides
per frameshift mutation. As expected, the rate of predicted HLA binding peptides mirrored the
somatic mutation rate per tumor type (Figure 3.5). We used two approaches to study the re-
lationship between predicted binding affinity and immunogenic neoantigens that induce CTLs.
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A retrospective application of our pipeline to published immunogenic tumor neoantigens (i.e.
in which reactive CTLs were observed in patients) demonstrated that the vast majority (91%)
of functional neoantigens are predicted to bind HLA with IC50<500nM (with ∼70% of wild
type counterpart epitopes predicted to bind at a similar affinity) (Table 3.2, Table 3.3). This
test using a gold standard set of neoantigens confirms that our pipeline largely classifies true
positives correctly. A prospective prediction of neoepitopes followed by functional validation
showed that 6% (3/48) of our predicted epitopes were associated with neoantigen-specific T cell
responses in patients – comparable to the rate of 4.8% found recently for melanoma (Robbins
et al. (2006)). The low proportion does not necessarily imply low prediction accuracy for the
algorithm. Rather, number of true neoantigens is greatly underestimated by our experiments
because: (i) allo-HSCT is a general cellular therapy likely to induce only a small number of
neoantigen-specific T cell memory clones; and (ii) our T cell expansion methods are not sensi-
tive enough to detect nave T cells that represent a much larger part of the repertoire but with
much lower precursor frequencies. Beyond the issue of prediction accuracy, we have also not yet
measured the frequency of CTLs that target neoORFs a class of neoantigens that we expect to
be more specific (for lack of a wild type counterpart) and immunogenic (as a result of bypassing
thymic tolerance). Furthermore, we have not considered peptides binding to the less common
HLA alleles because peptide binding predictions are not yet accurate for these alleles. Future
improvements in predictive algorithms, and eventually development of direct physical methods
for detecting HLA-binding peptides using mass spectrometry, will make it possible to more
effectively select neoantigens presented by tumor HLA proteins. Considering the limitations
described here, we conclude that there will be many more neoantigens per tumor.
Given the large number of candidate neoantigens, are there additional considerations that
could help select the most useful antigens for targeting tumors? First, is it important to
have high RNA or protein expression for CTLs to detect HLA-peptide complexes? While no
empirical studies have tested this question in human trials, it appears that very low levels (i.e.
even a single peptide-HLA protein) may be sufficient for a cell to be targeted by a CTL (Sykulev
et al. (1996)), suggesting that high expression may not be required for inclusion of a neoantigen
in a vaccine. Second, while theory suggests that essential cancer genes (drivers) are less likely to
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Table 3.2 HLA-peptide binding affinities of known functionally derived immunogenic mutated
epitopes across human cancers using NetMHCpan. Epitopes from missense muta-
tions (NSCLC: non-small cell lung cancer; MEL: melanoma; CLL: chronic lympho-
cytic leukemia; RCC: clear cell renal carcinoma; BLCA: bladder cancer; NR: not
reported;). Yellow: IC50 < 150 nM, green: IC50 150–500 nM and grey: IC50 > 500
nM. We discovered that these epitopes fell into 4 groups. Group 1: Mutated and
wildtype peptides with IC50<150 nM; Group 2: mutated and wildtype peptides
with IC50 150–500 nM; Group 3: mutated peptide with IC50 < 150 and wildtype
peptide with IC50 > 500nM and Group 4: mutated and wildtype peptides with
IC50 > 500nM.
42
Table 3.3 HLA-peptide binding affinities of known functionally derived immunogenic mutated
epitopes across human cancers using NetMHCpan: Minor alleles. Epitopes from
minor histocompatibility antigens (MM: multiple myeloma; HM: hematological ma-
lignancy; B-ALL: B cell acute lymphocytic leukemia).
develop resistance under immune pressure, it is not clear that the three neoantigens (mutated
FND3CB, ALMS1, C6orf89) found in our study to induce long-lived CTLs play any functional
role in the tumor. Third, the clonality of the mutations may be important. We found that the
three CLL neoantigens were clonal or near-clonal (data not shown (Carter et al. (2012))). We
thus suggest that CTLs associated with clinical responses can target tumor-specific mutations
that are present in the bulk of the cancer mass (whether recurrent or not). However, it is clear
that only large clinical trials can identify neoantigen properties that are important for targeting
tumors.
It is becoming clear that targeting multiple personal tumor epitopes is likely a useful thera-
peutic approach. In a recent study of the B16 murine melanoma model, HLA-binding neoanti-
gens were predicted based on tumor mutations. Mice that were immunized with the corre-
sponding mutated peptides developed CTLs specific to the mutated but not wild type peptide
and controlled disease therapeutically and prophylactically (Castle et al. (2012)). In addition,
recent studies in mice showing immune editing and escape to dominant CTL responses support
the notion of targeting multiple epitopes to avoid resistance (DuPage et al. (2012), Matsushita
et al. (2012)). A prospective clinical trial should now be possible to design based on our pipeline




Figure 3.3 The numbers and affinity distributions of peptides predicted from 31 CLL cases
with available HLA typing. Patients expressing the 8 most common HLA -A, -B
alleles in the Caucasian population are marked in grey.
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Figure 3.4 Application of the NetMHCpan prediction algorithm to functionally-defined
neoepitopes and CLL cases. (A) The amino acid sequences of 33 functionally iden-
tified cancer neoepitopes reported in literature (table 3.2, Table 3.3) were tested by
NetMHCpan, and the resulting predicted binding (IC50) to their known restricting
HLA allele are presented, sorted on the basis of predicted binding affinity. (B) Dis-
tribution of the number of predicted peptides with HLA binding affinity < 150 nM
(black) and 150–500 nM (grey) across 31 CLL patients with available HLA typing
information (Table 3.3). (C) Peptides with predicted binding (IC50 < 500 nM by
NetMHCpan) from 4 patients were synthesized and tested for HLA -A and -B allele
binding using a competitive MHC I allele-binding assay. The percent of predicted
peptides with evidence of experimental binding (IC50 < 500 nM) are indicated.
(D) The distribution of gene expression for all somatically mutated genes (n=347)
from 26 CLL patients, and for the subset of gene mutations encoding neoepitopes
with predicted HLA binding scores of IC50 < 500 nM (n=180). No-low: genes
within the lowest quartile expression; medium: genes within the 2 middle quartiles
of expression; and high: genes within the highest quartile of expression.
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Figure 3.5 Estimation of tumor neoantigen load across cancers. (A) Box plots comparing
overall somatic mutation rates detected across cancers by massively parallel se-
quencing. LUSC: Lung squamous cell carcinoma, LUAD: Lung adenocarcinoma,
ESO AD: Esophageal adenocarcinoma, DLBCL: Diffused large B-cell lymphoma,
GBM: Glioblastoma, Papillary RCC: Papillary renal cell carcinoma, Clear Cell
RCC: Clear cell renal carcinoma, CLL: Chronic lymphocytic leukemia, AML:
Acute myeloid leukemia. The distributions (shown by box plot) of (B) the number
of missense, frameshift and splice-site mutations per case across 13 cancers, (C) the
summed neoORF length generated per sample and of the predicted neopeptides
with IC50 < 150 nM (D) and with < 500 nM (E) generated from missense and
frameshift mutations. For all panels, the left and right ends of the boxes represent
the 25th and 75th percentile values, respectively, while the segment in the middle
is the median. The left and right extremes of the bars extend to the minimum and
maximum values.
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CHAPTER 4. MICRORNA REGULATORY NETWORK INFERENCE
IDENTIFIES MIR-34A AS A NOVEL REGULATOR OF TGF-β
SIGNALING IN GLIOBLASTOMA
Modified from a paper published in Cancer Discovery 2012
Giannicola Genovese?, Ayla Ergun?, Sachet A. Shukla?, Benito Campos, Jason Hanna,
Papia Ghosh, Steven N. Quayle, Kunal Rai, Simona Colla, Haoqiang Ying, Chang-Jiun Wu,
Sharmistha Sarkar, Yonghong Xiao, Jianhua Zhang, Hailei Zhang, Lawrence Kwong, Katherine
Dunn, Wolf Ruprecht Wiedemeyer, Cameron Brennan, Hongwu Zheng, David L. Rimm, James
J. Collins, and Lynda Chin
? denotes equal contribution
4.1 Introduction
Glioblastoma is the most common primary brain tumor in adults. Patients with newly
diagnosed glioblastoma have a median survival of 12 months with generally poor responses to
chemoradiotherapy(Furnari et al. (2007)). Recent genome-wide profiling studies have shown
extensive genetic heterogeneity among glioblastoma samples with distinct molecular subtypes;
that these transcriptomic subtypes reflect distinct underlying biology is supported by observed
differences in clinical outcome of the patients (Verhaak et al. (2010)), enrichment of different
genomic and epigenetic alterations within each subtype, and differential activation of major
signaling pathways (Brennan et al. (2009), Noushmehr et al. (2010)).
Noncoding RNAs have emerged as an important class of regulatory molecules in both normal
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and neoplastic development. MicroRNA (or miR) is a class of noncoding small RNAs produced
by RNA polymerase II as hairpins of longer precursor RNAs that are subsequently processed
to approximately 22-nt-long fragments by RNase III enzymes, Drosha and Dicer. Mature miRs
regulate gene expression by promoting mRNA degradation or by inhibiting mRNA translation
(Bartel (2004), Krol et al. (2010)). The connection between miRs and cancer was first impli-
cated by their genomic alteration and dysregulated expression in various human tumors (Calin
et al. (2004)). Multiple miRs have since been identified to promote or suppress oncogenesis
in various tumors, presumably by modulating gene expression in the oncogenic and tumor
suppressor networks. In addition, recent studies have proposed new mechanisms of miRm-
RNA regulation such as modulation of mRNA with competitive miR-binding sites (sponge
interactions) or mRNAs that affect constituents of the miR regulatory machinery (nonsponge
interactions; Sumazin et al. (2011), Karreth et al. (2011), Tay et al. (2011)).
Global views of the relationship between miR and mRNA expression have been reported.
For instance, Su and colleagues (Su et al. (2011)) used integrative genomics and genetic tech-
niques to characterize the roles of mouse miRs within the mouse liver miR:mRNA network;
Dong and colleagues (Dong et al. (2010)) deciphered the pathway connecting mutations under
the glioblastoma miRmRNA expression network; Mestdagh and colleagues (Mestdagh et al.
(2011)) established the miR body map online resource to dissect miR function through integra-
tive genomics; Grigoryev and colleagues (Grigoryev et al. (2011)) presented the genome-wide
miR regulation of T-lymphocyte activation through the mapped miR, mRNA, and protein
networks; and Sharbati and colleagues (Sharbati et al. (2011)) studied macrophage infection
via an integrated miRmRNA network. In these global integrative miR:mRNA network analy-
ses, either general correlation coefficient methods or putative miR target prediction methods
have been used to construct or map miR:mRNA connections. These approaches preferentially
quantify linear dependencies between pairwise variables.
Recognizing that the functional relationship between 2 variables in cancer is not necessarily
linear, we explored a mutual information-based approach in this work that scores miR-mRNA
interaction strength on the basis of relevant expression contexts. This mutual information-
based approach has been used recently by Sumazin and colleagues (Sumazin et al. (2011)) to
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uncover a novel class of modulators of miR:mRNA interactions. Here, we applied the Context
Likelihood of Relatedness (CLR; Faith et al. (2007)) network modeling algorithm to generate
pairwise measures of associations on the basis of mutual information through calculation of
the entropy. At the heart of the CLR algorithm is a unique statistical background correction
test which uses the full set of mutual information values to estimate a significance value for
each miRmRNA pair under a given observed network context (see Supplementary Informa-
tion). The algorithm evaluates the mutual information value of a miR:mRNA pair against the
background mutual information distribution of all mRNAs in the data set with the miR, as
well as with the distribution of mutual information values of all miRs with the mRNA under
consideration. A combined z-score summarizing these 2 comparisons is generated, and the list
of all such pairwise z-scores is subsequently used to generate P values by comparing with the
normal distribution. A stringent false discovery rate of 5% is finally applied to identify putative
miRmRNA regulatory edges. Interactions whose mutual information values are outliers in the
right tails of the pertinent context background distributions of mutual information scores have
the greatest likelihood of being identified as significant. This background correction method
allows the CLR algorithm to filter out those edges between miRs and mRNA that have spurious
similarities with large numbers of other genemiR species.
Network inference approaches in general have a tendency to have high false positive rates
which can be partly explained by the noisy nature of the input data. The CLR approach
is no exception and is also not well-suited to inferences of directionality and differentiating
between direct and indirect interactions. We try to compensate for these limitations by using
different complementary approaches and filters for assessing the biological significance and
relative importance of edges, miRs, transcription factors etc to arrive at a manageable list of
candidates for experimental validation.
The Cancer Genome Atlas (TCGA) has characterized the genomes of glioblastoma on mul-
tiple dimensions including coding and noncoding RNAs (TCGA (2008)). We applied the CLR
modeling algorithm to this multidimensional data set to infer putative regulatory relationships
(edges) between miRs and mRNAs in glioblastoma. Specifically, we were interested in direc-
tional miRmRNA interactions where the miR downregulates mRNA expression either directly
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through binding or indirectly through intermediary effectors. Against this global network, we
explored the functional relationship between miRs and mRNAs in gliomagenesis.
4.2 Methods
4.2.1 Application of CLR to the TCGA data set
A total of 290 GBM samples that had matched mRNA and miR were used in the analysis.
Because the CLR algorithm relies on variability in the dataset to estimate significant edges,
we first filtered the 534 miR and 17814 mRNA species profiled on the corresponding platforms
based on the variability they showed in the 290 GBM samples. We chose to apply CLR on
those miR and mRNA transcripts, which had variance across the 290 samples, higher than the
median variance across all species. This yielded 267 miR and 8907 transcripts among which we
looked to infer regulatory relationships. Similarly for the subtype specific analysis, we required
that the miR and mRNA transcripts, have variance across their respective subtypes, higher
than the median variance across all species in that subtype.
4.2.1.1 The CLR Method
For the analysis of the matched miR:mRNA expression profiling data we utilized a previ-
ously described method, namely the CLR (Context Likelihood of Relatedness) algorithm (Faith
et al. (2007)). The CLR algorithm builds upon the relevance network strategies, by applying a
background correction step. After computing the mutual information between regulators and
their potential target genes, CLR calculates the statistical likelihood of each mutual informa-
tion value within its network context. The algorithm compares the mutual information between
a miR/gene pair to the background distribution of mutual information scores for all possible
miR/gene pairs that include either the miR or its target. After this background correction, the
most probable interactions are those whose mutual information scores stand signicantly above
the background distribution of mutual information scores. This step removes many of the false
correlations in the network by eliminating promiscuous cases in which one transcription factor
weakly covaries with a large numbers of genes or one gene weakly covaries with many transcrip-
51
tion factors. Such promiscuity arises when the assayed conditions are inadequately or unevenly
sampled, or when microarray normalization fails to remove false background correlations due to
inter-lab variations in methodology. The mutual information for two discrete random variables










where P (xi) is the probability that X = xi. For genes, X and Y represent a transcription
factor and its potential target gene, and xi and yi represent particular expression levels.
CLR uses the matrix of mutual information (MI) values between all probe sets on the array.
The CLR algorithm estimates a likelihood of the mutual information score for a particular pair
of genes, i and j by comparing the MI value for that pair of genes to a background distribution
of MI values. The background distribution is constructed from two sets of MI values: MIi, the
set of all the mutual information values for gene i (in row or column i), and MIj , the set of
all the mutual information values for gene j (in row or column j). Because of the sparseness
of biological regulatory networks, most MI scores in each row of the mutual matrix represent
random background mutual information. We approximate this background MI as a joint normal
distribution with MIi and MIj as independent variables and compute the z-score for each of
those distributions
Zi =




MI(jth entry in ith column)−mean(jth column)
σ(jth column)
(4.3)





where Zi and Zj are the z-scores of the marginal distributions (Whitlock (2005)). The new
metric is then used as a measure of the relationships among the genes. P-values corresponding
to the entire set of z-scores are then calculated by comparing to the normal distribution; a
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stringent FDR of 5% is finally applied to the computed p-values which defines the inferred
network. As can be seen from Figure 4.1, CLR identifies several connections in the main body
of the network that would have been missed by the relevance network framework.
Figure 4.1 CLR characteristics. The blue line shows the distribution of measures of associa-
tion (mututal information and correlation) between all miR:mRNA pairs. The red
line shows the distribution of measures of association values for all CLR-identified
miR:mRNA pairs.
4.2.2 Filters
Three different filters were implemented in order to prioritize candidates for experimental
validation.
4.2.2.1 Copy number filter
We hypothesized that edges in the network where one or both nodes were in regions of copy
number alteration had evidence of additional mechanism(s) of dysregulation and were there-
fore had greater biological relevance. Segmented copy number data were downloaded from
the TCGA data portal (http://tcga-data.nci.nih.gov/tcga) and were processed using the CN
Tools (http://www.bioconductor.org/packages/2.6/bioc/html/CNTools.html) package of the
Bio-conductor project to derive a matrix with genes as rows and samples as columns by assign-
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ing each gene the corresponding segment value for each sample. The SGOL (Segment Gain or
Loss) score was then calculated for each gene by summarizing the positive or negative values for
a given gene across samples using the cghMCR package
(http://www.bioconductor.org/packages/2.6/bioc/html/cghMCR.html). Genes with large pos-
itive and small negative SGOL scores have high amplitude and/or recurrence of alterations
across samples. The threshold used for a single sample was >0.3 for gain and <-0.3 for loss.
Thresholds of SGOL > 28 and SGOL <-32, corresponding to the 90th percentiles of gain and
loss SGOL analyses respectively, were set to filter genes based on copy number data.
4.2.2.2 Gene expression affected by copy number filter
We further hypothesized that genes that displayed expression changes that was indeed
driven by DNA gain or loss were better experimental targets. Gene weight analysis can be
used to evaluate the influence of copy number alterations on gene expression (Carrasco et al.
(2006)). In this work, gene weight analysis was applied to find genes or miRs with high
correlation between their expression and copy number levels. For a particular probe gene/miR,
expression values of all samples were divided into two groups according to copy number status.
For example, expression in tumors with copy number alterations (CNA) compared to without





where mT ,mR and σT ,σR denote the mean and standard deviations for expression values for
two groups T and R respectively. Statistical significance was determined by permuting sample
labels for expression data. A low p-value indicates a strong correlation between the expression
and copy number level of the gene or miR under consideration.
4.2.2.3 Direct targets filter
We were interested in priortizing miR:mRNA edges where the possibility of a direct molec-
ular interaction between the two molecules was high. Based on the assumption that miRs
downregulate their target genes by binding to their 3′ UTR regions, we defined a subset of
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mRNA nodes as putative direct targets of their miR nodes based on the following parameters:
i) a significant negative correlation (Pearson correlation coefficient ≤ -0.3) between expression
of miR and mRNA; and ii) sequence-based prediction of interaction in all three databases,
namely Pictar, TargetScan and Miranda (Chen and Rajewsky (2006), Grimson et al. (2007),
Krek et al. (2005), Lewis et al. (2005), Betel et al. (2008)).
4.2.3 Identification of subtype-specific edges
To enumerate all miR:mRNA associations that are subtype-specific, we next repeated CLR
modeling within each molecular subtype as defined by TCGA (classical, neural, proneural,
mesenchymal on the assumption that subtype-specific relationships would have a high likelihood
of being buried in the noise of a global network. We performed a permutation test as follows:
We first apply the CLR algorithm to samples belonging to the 4 different subtypes sepa-
rately. Significances of miR:mRNA associations that are identified exclusively in one subtype
are assessed by three permutation tests as follows. Let us denote the 4 subtypes by A, B, C and
D, with A being the subtype in which the uniqueness of a given correlation is being evaluated.
(i). Compute the difference in miR:mRNA correlations between subtype A and one of the other
subtypes, say subtype B.
(ii). Permute the sample labels between subtypes A and B and compute the difference in corre-
lations in the new set. Repeat this for a 1000 permutations to get the background distribution.
(iii). The p-value is assigned to the original difference calculated in step (i) by comparing it
against the background distribution.
(iv). Repeat steps (i)-(iii) for subtypes C and D, i.e. compare A to C and compare A to D
separately.
(v). If the three p-values computed in steps (i)-(iv) are all less than 0.01, the correlation is
considered unique to subtype A.
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4.3 Results
Application of CLR identified a total of 26,297 edges between 254 miR hubs and 6,152
mRNA nodes.
4.3.1 Copy number filter
Integration with copy number profiles revealed that a third (34.1%) of the miR nodes or
mRNA nodes linked to CLR-inferred edges resided in regions of copy number aberration, and
less than 3.9% of all edges had both miR and mRNA localized in regions of genomic alterations
(Figures 4.2 and 4.3). That these edges are subjected to additional levels of deregulation hints
at their biological relevance in GBM.
Figure 4.2 CLR network grouped by connectivity among miRs and mRNAs in regions of
copy number aberration. Size of the node represents the number of edges between
the miR and mRNAs in each group.There are 9 subnetworks represented. Edges
in the network where both participating miR and mRNA are in regions of copy
number alterations account for less than 3.9% of the total connectivity (green
circles). Edges where either the participating miR or the mRNA is in region of
gain or loss, but not both, account for 34.1% of the network (orange circles).
Approximately 62% of the network involves miRs and mRNAs without evidence
of genomic alterations in glioblastoma (blue circle).
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Figure 4.3 Network of CLR edges where both miR (diamonds) and mRNA (circles) are in
regions of copy number gain (purple nodes) or loss (green nodes).
4.3.2 Direct targets filter
Application of the direct targets filter identified only 45 (0.17%) of the 26,297 CLR-inferred
edges as putatively direct (Figure 4.4, Supp Table 3), suggesting that the predominant relation-
ship between miR and mRNAs may be indirect, possibly through modulation of intermediary
molecules such as transcription factors.
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4.3.3 Subtype expression differences drive the identification of edges in the net-
work
Four predominant subtypes classical (CL), neural (NE), proneural (PN) and mesenchymal
(MS) - have been identified in GBM based on transcriptomic analysis (Verhaak et al. (2010))
and these have been shown to have biological and clinical significance. As a first step to
mine the computed network, we asked whether the CLR-inferred global network captures the
salient transcriptomic features of the four molecular subtypes of GBM. Here, we looked for
differential expression of the miR nodes and mRNA nodes between any two molecular subtypes.
Interestingly, the variability among molecular subtypes appeared to be the predominant drivers
of relationships defined by CLR. We find that in 67% of CLR edges, the mRNA changes levels
between two subtypes in one direction while the miR that it is associated with changes levels in
the opposite direction (p < 0.001). Figure 4.5 shows one such identified edge between mir-34a
and PDGFRA. It is clear from the figure that PN samples have high levels of PDGFRA and
low levels of mir-34a and the reverse trend is apparent for the MS samples. While the difference
in expression between the subtype signature genes is not surprising, it is striking that the CLR-
identified miRs associated with these genes should show a reciprocal and opposite change of
expression along with their mRNA nodes. In particular, the most significant difference was
observed between proneural and mesenchymal subtypes where nearly half of the edges in the
global network (or 12,673 edges, 48%) reflect the differences between these two subtypes. This
observation suggested that miR regulation of mRNA may play an important role in defining
the molecular signatures of these two subtypes. We postulate that these strong reciprocal
differences in mRNA and miR expression levels between two subtypes (predominantly between
PN and MS) might be the underlying effect that is driving the identification of several CLR
edges in the global analysis.
4.3.4 Discriminatory miRs between the PN and MS subtypes
To explore further the role of miRs in defining the molecular signatures of subtypes, we
looked for CLR-inferred edges among the 685 genes, comprising genes overexpressed in the
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four subtypes, which was used by Verhaak et al (Verhaak et al. (2010)). Of these 685 genes,
506 of them (73%) have edges to a miR node in the global CLR network. Conversely, of the
2,984 inferred edges to these 506 subtype-classifier genes, a disproportionate number (70%) of
the edges are part of the PN and MS subtype signatures (e.g. 328 to classical, 560 to neural,
858 to PN and 1,238 to MS signature genes), suggesting that specific miR nodes may contribute
to gene signatures underlying these two molecular subtypes.
To identify a core network of PN and MS differences, we looked for miR hubs that had
significant number of connections to either PN and MS gene signatures, which were defined as
genes that are highly expressed in the respective groups. We scored each miR hub with:
score mirna(i) =
d1− d2
(Lmes+ Lpro)/2 + Lhub
(4.6)
where d1 is the number of MS signatures genes which are negatively correlated with the miR
expression and the number of PN signature genes which are positively correlated with the miR
expression; d2 is the number of MS signatures genes which are positively correlated with the
miR and the number of PN signature genes which are negatively correlated with the miR. Lmes
is the size of the MS signature, Lpro is the size of the PN signature and Lhub is the number of
connections identified by CLR for the miR. This score would be high in two cases; miRs whose
edges were to genes that showed negative correlation with MS genes and positive correlation
with PN genes or vice versa. The score obtained for each miR was Z-transformed and a false
positive rate of 0.001 was applied to identify 8 miR nodes with the greatest discriminatory
potential between the PN and MS subtypes. Table 4.1 shows the overlap of subtype signature
genes with the CLR targets of mir-34a, which is one of the 8 identified discriminatory miRs.
Figure 4.6 shows a heatmap of correlations of the PN and MS signature genes that are associated
with these 8 miRs by CLR. These correlations follow a definite pattern 5 miRs have strong
negative correlations with PN genes and positive correlations with MS genes; the other 3 miRs
show an opposite trend.
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Table 4.1 Overlap of mir-34a targets with subtype signature genes
4.3.5 miR-34a
We wanted to pick a miR for thorough experimental follow-up. The 8 identified discrimina-
tory miRs were enlisted for functional genomic screens in vitro and in vivo. One such result is
highlighted in Figure 4.7 which shows that only mir-34a was able to completely block tumori-
genesis in vivo. In parallel to the functional genetic screens, we also explored the biological
relevance of these miRs to human GBM through integrative analyses. Based on the thesis that
biologically important genetic elements will be subjected to genomic alterations as an alter-
native mechanism of deregulation, we integrated copy number information on these 8 miRs
and their 2,699 mRNA nodes to look for genomic evidence of relevance for either the miRs
or their mRNA nodes. As detailed in Table 4.2, three of these 8 miRs (miR-34a, miR-181c,
miR-181d) were resident in regions of genomic alteration, 2 with corresponding expression al-
terations. Similarly, 185 of the mRNA nodes connected to these 8 miRs were found to be
targeted for copy number alterations, 46 (∼25%) of which showed corresponding expression
alterations. Correspondence of expression and copy number change was evaluated using Gene
Weight Analysis. When applying the rules for putative direct-target definition based on expres-
sion correlation and sequence-level prediction by three commonly utilized algorithms (Pictar,
TargetScan, Miranda), we found that miR-34a is the only miR node that resides in a region of
frequent loss and harbors a putative direct CLR-edge, PDGFRA that is in a region of genomic
gain. Furthermore, we asked whether expression of any of the miRs tracks with prognosis in
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Table 4.2 Integrating copy number and direct targets filters with the network defined by the
8 miRs
Table 4.3 Survival analysis results
all GBM or within a specific GBM subtype. As summarized in Table 4.3, when dichotomized,
miR-34a expression was the only miR with significant prognostic value (Bonferroni-adjusted p
value = 0.0047) with a Hazard Ratio of 2.2. It has already been established in literature that
PN samples have a better prognosis than the other subtypes. Importantly, miR-34a expression
does not simply identify PN subtype tumors which are known to have overall better survival
(Verhaak et al. (2010)); instead, high miR-34a expression defines a subset of PN GBMs with
poor prognosis similar to that of the other subtypes (Figure 4.8). In other words, miR-34a is
a prognostic biomarker for aggressive PN GBM. Collectively, the functional genetic data and
integrative analyses singled out miR-34a as a strong candidate for further validation.
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4.3.6 mir-34a and the transcription factor hypothesis
Consistent with the observation in the global CLR network, less than 1% of the miR-34a
subnetwork (three of the 342 nodes or 0.88%) were computationally predicted to be direct,
suggesting that the majority of the miR-34a putative regulatory relationships was not mod-
ulated by direct miR-mediated RNA degradation/translation impairment. We thus postulate
that indirect mechanisms such as transcriptional regulation mediated through intermediate
regulators, e.g. transcription factors, may be at play. To identify such intermediates in the net-
work, we performed an in silico enrichment analysis for transcription factor (TF) binding sites.
Transcription factor binding site motifs from the TRANSFAC database (release 10.1, Matys
et al. (2006)) were identified in genomic regions comprising 8kb upstream and 2kb downstream
of the transcription start site of genes based on coincidental prediction by the CisGenome
(conservation cutoff = 50, likelihood ratio = 500, third order background Markov model) and
MotifScanner (prior probability of 1 motif copy = 0.9) programs (Aerts et al. (2003), Aerts
et al. (2005), Ji et al. (2006)). Two sets of genes corresponding to mir-34a CLR targets that
define either the PN or MS signatures were compared for differential over-representation of
transcription factor binding sites using this approach. For each TF the proportion of genes
with at least one corresponding binding site were compared between the two groups. 34 ver-
tebral transcription factors were thus identified (p.val < 0.05). This list was further screened
for transcription factors that were overexpressed and had a statistically significant negative
correlation with mir-34a (corr < -0.3, p-val < 0.05) in the PN group. We ended up with 3
potential TF candidates (Table 4.4). PBX was not expressed in our cell systems; Myc and
Smad4 were experimentally validated as actual intermediaries through which mir-34a effects
its subtype specific action. In parallel, the mir-34a:PDGRA edge was also validated as a direct
interaction. Figure 4.9 summarizes our current mode of action of mir-34a in GBM.
4.3.7 Identification of subtype-specific edges
Several subtype-specific edges were identified by the subtype-specific procedure described
in the methods section. For example, the miR-195:SPRY4 regulatory relationship was not
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Table 4.4 Transcription Factor Analysis
observed in the global network but was specific to the proneural subtype (Figure 4.10). Corre-
spondingly, we found that miR-195 was capable of modulating SPRY4 expression in E6/E7T
immortalized human astrocytes, with functional impact on proliferation, but failed to do so in
two established GBM cells, suggesting that miR regulation of its mRNA targets can be highly
context-specific.
4.4 Discussion
Glioblastoma is a heterogeneous disease characterized by distinct molecular subtypes under-
lying different biologic behaviors and response to therapies. Leveraging the multidimensional
TCGA data set, reverse-engineering with the CLR algorithm has provided an inferred map of
the putative miR mRNA regulatory network in glioblastoma. Integrating this network model
with molecular subtype denition and functional genomic screen, as well as in silico sequence-
based target prediction and promoter analysis, we prioritized miR-34a for downstream mech-
anistic studies. These studies uncovered a novel regulatory network emanating from miR-34a,
which acts as a tumor suppressor in proneural-like glioblastoma, in part, through direct action
on PDGFRA as recently shown by Silber and colleagues (Silber et al. (2012)) in addition to
commandeering of the SMAD4 transcriptomic network to regulate ID1 and ID3 levels. That the
majority of mRNAs computed to link to a miR node appears to be regulated indirectly through
transcription factors, such as SMAD4 (this study) and MYC (Christoffersen et al. (2010), Choi
et al. (2011)) likely serves as an amplier of an effect of miR on the global transcriptome. This
nding thus provides a rationale for an alternative approach to inhibit transcription factor ac-
tivity through modulating its upstream miR regulatory node. In sum, this work illustrates
not only the power of comprehensive cancer genomic data sets such as that of TCGA and
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the importance of mining and interpreting such data sets in the context of cancer biology but
also the value of computational and experimental models in enabling an understanding of the
underlying complexity of the disease.
Although miR-34a has been implicated in multiple cancer types (Hermeking (2010)), its
roles in the regulation of SMAD4-ID1-ID3 have not been previously suggested. While the
relationship between PDGFRA and miR-34a is predicted by sequence-based algorithms, the
relationship between miR-34a and SMAD4 or its downstream ID1 and ID3 are not; therefore,
the hypothesis that they could be mediators of miR-34a activity came only through unbi-
ased analysis for transcription factorbinding site enrichment in the promoters of CLR-inferred
mRNA nodes linked to miR-34a. This reinforces the power of global system- biology approaches
in generating unanticipated hypotheses.
Finally, our findings in this study have potential clinical application, as miR-34a expression
level is shown in 2 independent cohorts of glioblastoma to stratify patients into good and
poor prognosis subgroups with signicant difference in overall survival. Furthermore, within the
TCGA cohort, we found that miR-34a carries signicant overlap in prognostic signicance with
glioma-CpG island methylator phenotype (G-CIMP) status (Noushmehr et al. (2010); data not
shown), suggesting a possible mechanistic relationship between miR-34a and G-CIMP, although
elucidation of the molecular basis for this relationship will require further studies.
Previous studies have reported miR-34a expression level as a prognostic parameter. For
instance, in pancreatic ductal adenocarcinoma, miR-34a loss (i.e., low to no expression) is
associated with a decreased survival probability (Jamieson et al. (2012)); in other words, miR-
34a-expressing pancreatic ductal adenocarcinoma has a relatively better survival. In breast
cancer, although high miR-34a expression is correlated with poor prognosis factors including
positive nodal status, high tumor grade, estrogen receptor negativity, HER2 positivity, and
high proliferation rate, after adjusting for these known prognostic parameters in multivariant
analysis, high miR-34a expression is in fact associated with a lower risk of recurrence or death
from breast cancer (Peurala et al. (2011)), indicating that high levels of miR-34a are a good
prognostic factor. In contrast to these previous studies, our analyses of 2 independent cohorts
of glioblastoma showed that miR-34a low-expressing glioblastomas have better outcome with
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longer overall survival. In other words, glioblastoma tumors driven by inactivation of miR-34a
are less aggressive than glioblastomas that evolve through deregulation of other genetic ele-
ments. The differences in prognostic signicance of miR-34a loss in different tumor types likely
reect the modulatory effects of preexisting genetic alterations and the specic susceptibility of
different cell types to the aberrant activation of any given pathway. This is not dissimilar to the
case of another glioma gene, IDH1, whose specic point mutation affecting a key residue in the
protein (R132) has been shown to be oncogenic. Interestingly, gliomas carrying this mutation
in IDH1 as well as analogous mutations affecting IDH2 have a signicantly better prognosis (Lu
et al. (2012), Parsons et al. (2008), Yan et al. (2009), Koivunen et al. (2012)). On the other
hand, in cytogenetically normal acute myelogenous leukemia carrying NPM1 mutations, IDH1
mutations at the same residue are a poor prognostic factor as patients with IDH1 mutations
do worse (Marcucci et al. (2010), Paschka et al. (2010)). In summary, we illustrate here that
computational network modeling of the complex interrelationships among diverse genetic ele-
ments can generate a logical framework in which to explore and understand the genetics and
biology of cancers, and when integrated with disease knowledge and clinical annotation can
lead to discovery of new pathogenetic insights in addition to potential prognostic biomarkers or
therapeutic targets. In this regard, we believe that the results from this study should motivate
future efforts to explore the therapeutic implication of miR-34a reconstitution. The potent
tumor-suppressive activity in our preclinical models would suggest possible therapeutic benet
of miR-34a reconstitution by tumor-targeted delivery in low miR-34a-expressing glioblastoma.
In view of its mechanism of action through PDGFRA, MYC, and SMAD4, one may further
speculate that reconstitution of miR-34a could represent an attractive strategy to deliver com-
bination therapy against multiple bona fide cancer gene targets.
4.4.1 Shortcomings of the CLR algorithm
The CLR algorithm introduces a very complex correlation structure between the computed
Z-scores since the value in each cell is a function of the mutual information distributions along
the corresponding row and column. This is evident in the observed p-value distribution as
shown in Figure 4.11. It is clear that the assumption of independence is strongly violated. A
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lesser concern is that the assumption of normality of the mutual information values is also not
true.
We developed a novel approach for miR regulatory network inference that better deals the
issues seen in the CLR algorithm. The algorithm models gene expression as a function of
methylation and copy number status of the gene. The reduced model of each gene is com-
pared against the full model that includes additional terms capturing miR expression. MiRs
that result in a significant improvement in the goodness of fit of the full model are identi-
fied as putative regulators of the gene. The resulting p-value distributions are well-behaved
and amenable to robust statistical inference. Three sequence prediction algorithms - Miranda,
Pictar and Targetscan - are subsequently used to prioritize miR:gene associations for experi-
mental validation. The application of the approach to other cancer types should help delineate
disease-specific miRNA:mRNA regulatory networks.
4.4.2 Integrated model





ci ≡ copy number of gene in individual i
mij ≡ beta value of methylation probe j of the gene in individual i
For all miRs rk, the following two models are computed:















+ rik + 
 ∼ N(0, σ2)
(4.7)
The improvement of fit to the model of expression of the gene resulting from including
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∼ F (dfl1 − dfl2k , dfl2k) (4.8)
The process is repeated for all genes. The distribution of the resulting set of p-values
approximate the theoretically expected mixture of uniform and beta (Figure 4.12). miR:mRNA
edges significant at 5% FDR define the final network.
4.4.3 Results
The integrated model was applied to a TCGA repository of 482 matched samples with
expression data across 470 miRs and 12042 genes. 17539 miR:mRNA edges were discovered at
the 5% level involving 223 miRs and 3328 genes (Figure 4.13).
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Figure 4.4 Putative direct-target subnetworks among CLR-identified edges in glioblastoma.
miRs are represented as green diamonds and genes as circles; classical signature
genes (gray), neural signature genes (dark green), proneural signature genes (red),
mesenchymal signature genes (blue), genes not in any of the molecular subtype
signatures (pink). CL, classical; MS, mesenchymal; NL, neural; PN, proneural.
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Figure 4.5 mir-34a:PDGFRA edge. Proneural samples have high levels of PDGFRA and low
levels of mir-34a and the reverse trend is apparent for the mesenchymal samples.
Figure 4.6 Heatmap of correlations between 8 most discriminative miRs with proneural (PN)
and mesenchymal (MS) signature genes in the CLR network. Each cell in the
heatmap is the correlation between the corresponding miR and signature gene
across samples.
69
Figure 4.7 mir-34a blocks tumorigenesis in vivo. Nude mice were transplanted with prema-
lignant proneural-like cells and transduced with 6 pre-miRs corresponding to 8
discriminant miRs or the GFP control (n = 10 per group). miR-34a and miR-142
potently impaired tumorigenesis when compared with GFP control.
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Figure 4.8 Prognostic value of mir-34a within the proneural subtype. KaplanMeier survival
analysis of patients in the TCGA data set (n = 271). Low expression of miR-34a
stratifies a subgroup of patients with proneural glioblastoma with a significant sur-
vival advantage compared with others in TCGA cohort (log-rank P = 1.12×10−5).
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Figure 4.9 mir-34a model of action in GBM
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Figure 4.10 Subtype-specific edge example: mir-195:SPRY4
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Figure 4.11 Distribution of p-values by CLR. The complex correlation structure introduced
by CLR results in a significantly skewed distribution.
Figure 4.12 Distribution of p-values by integrated modeling. The distribution is well-behaved
and has a shape similar to the theoretically expected mixture of a uniform and a
beta.
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Figure 4.13 Top 1% of the inferred regulatory network (176/17539) edges)
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CHAPTER 5. SUMMARY
5.1 HLA typing and mutation detection
Recent large scale whole exome sequencing (WES) efforts have identified potentially func-
tional somatic changes in HLA type I genes in several tumor types (Stransky et al. (2011),
TCGA (2012a), Ding et al. (2008)) . These genes have also been implicated as possible drivers
of disease by virtue of recurrence in head and neck, lung squamous and diffuse large B-cell
lymphoma (Lawrence et al. (2014)). However the HLA loci are highly polymorphic and it is
likely that a considerable number of identified mutations are incorrect due to the reliance of
traditional approaches on the canonical reference genome for alignment. Prior determination
of the exact complement of alleles in such genomic regions of high variability should be useful
in increasing the sensitivity and specificity of standard somatic change detection algorithms at
these sites. We developed a method POLYSOLVER (POLYmorphic loci reSOLVER) compris-
ing alignment optimization followed by a novel model-based algorithm for accurate inference of
HLA class I alleles from WES data. We additionally presented a framework for sensitive and
precise detection of mutations in class I genes which is enabled by prior prediction of correct
reference alleles by application of POLYSOLVER on germline data. Application of POLY-
SOLVER on a set of 133 Hap Map samples with known HLA typing achieved 97% accuracy
at the protein level resolution. The use of POLYSOLVER in conjunction with somatic change
detection tools (Mutect, Strelka) on 2688 TCGA samples confirmed 30% of the events that
were already discovered using conventional approaches, while also identifying about 50% more
events. Morever events that were exclusively identified by standard methods were found to be
mostly false positives. The described methodology can easily be extended to other polymorphic
loci such as Type II HLA genes, MIC2A, MIC2B and TAP genes.
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5.2 Identification of personalized neoantigens in cancer patients
Genome sequencing has revealed a large number of shared and personal somatic mutations
across human cancers. In principle, any genetic alteration affecting a protein-coding region has
the potential to generate mutated peptides that are presented by surface HLA Class I proteins
that might be recognized by cytotoxic T cells. To test this possibility, we developed a pipeline
for the prediction and validation of such neoantigens derived from individual tumors and pre-
sented by patient-specific alleles of the HLA proteins. We applied our computational pipeline to
91 chronic lymphocytic leukemias (CLL) that had undergone whole-exome sequencing (WES).
We predicted 22 mutated HLA-binding peptides per leukemia (derived from ∼16 missense
mutations), and experimentally confirmed HLA binding for 55% of such peptides. Finally,
we computationally predicted HLA-binding peptides with missense or frameshift mutations for
several cancer types and predicted dozens to thousands of neoantigens per individual tumor,
suggesting that neoantigens are frequent in most tumors.
5.3 microRNA network inference
Leveraging The Cancer Genome Atlas (TCGA) multidimensional data in glioblastoma,
we inferred the putative regulatory network between microRNA and mRNA using the Con-
text Likelihood of Relatedness modeling algorithm. Interrogation of the network in context
of defined molecular subtypes identified 8 microRNAs with a strong discriminatory potential
between proneural and mesenchymal subtypes. Integrative in silico analyses, a functional ge-
netic screen, and experimental validation identied miR-34a as a tumor suppressor in proneural
subtype glioblastoma. Mechanistically, in addition to its direct regulation of platelet-derived
growth factor receptor-alpha (PDGFRA), promoter enrichment analysis of context likelihood
of relatedness-inferred mRNA nodes established miR-34a as a novel regulator of a SMAD4
transcriptional network. Clinically, miR-34a expression level is shown to be prognostic, where
miR-34a low-expressing glioblastomas exhibited better overall survival. This work illustrates
the potential of comprehensive multidimensional cancer genomic data combined with compu-
tational and experimental models in enabling mechanistic exploration of relationships among
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different genetic elements across the genome space in cancer.
We illustrate here that network modeling of complex multidimensional cancer genomic data
can generate a framework in which to explore the biology of cancers, leading to discovery of
new pathogenetic insights as well as potential prognostic biomarkers. Specifically in glioblas-
toma, within the context of the global network, promoter enrichment analysis of network edges
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